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11 - Introduction
This thesis is the result of a work that has the purpose of employing
innovative transport vectors for drug delivery based on
“magnetoliposomes”, which are liposomes loaded with magnetic
nanoparticles.
Since their discovery1, lipid vesicles have attracted growing interest
for their potential application as nanometer-scaled drug delivery
vectors2-5. The interest is mainly related to their biocompatibility,
their flexibility in composition and size, and their ability to
encapsulate both hydrophilic and hydrophobic molecules into the
aqueous pool6 or in the lipid bilayer7, respectively.
Magnetic nanoparticles can be efficiently encapsulated in lipid
vesicles and used for targeting drugs to a specific location, i.e.
diseased cells, using an external magnetic force8,9.
The leakage of the embedded drug can be activated through
destabilization of the carrier system by an external stimulus; in this
case the presence of magnetic nanoparticles in the aqueous pool or in
the lipid bilayer of magnetoliposomes allows to enhance the drug
leakage by applying an alternating magnetic field (AMF)9. In this work
a low frequency alternating magnetic field (LF-AMF), 0.1-6 kHz, was
applied to study drug release from magnetic vesicles in order to
minimize the hyperthermic contribution and investigate only the field
effect. Detailed information about the magnetic drug-carrier systems,
prepared and studied in this work, is given in paragraph 1.4, where
the aim of the project is deeply discussed after a brief introduction to
Nanotechnology.
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A general description about the syntheses and the characterization
methods of magnetoliposomes is reported in Chapter 2 (Methods),
while the magnetic vesicle preparation and their release behaviour
have been widely discussed in Chapters 3 and 4, respectively.
Considering that “drug delivery” is one of the most promising
applications of “Nanotechnology” in medicine, a general introduction
about the main applications of “nanomedicine” is given in the
following paragraphs. Moreover the properties of lipid vesicles and
magnetic nanoparticles were discussed in order to understand
magnetoliposome behaviour and their drug release properties.
1.1 Nanotechnology
Although Nanotechnology is a relatively recent field in scientific
research, the development of its central concepts happened over a
longer period of time. The first use of the term “Nanotechnolgy” was
in "There's Plenty of Room at the Bottom" a talk given by physicist
Richard Feynman at an American Physical Society meeting in 1959:
“The principles of physics, as far as I can see, do not speak against
the possibility of manoeuvring things atom by  atom”. Feynman
described the possibility of manipulating individual atoms and
molecules, using one set of precise tools to build and operate another
proportionally smaller set, and so on down to the needed scale. In the
course of this, he noted, scaling issues would arise from the changing
magnitude of various physical phenomena: gravity would become less
important, surface tension and van der Waals attraction would
become increasingly more significant, etc. In the 1980s the basic idea
of this definition was explored in much more depth by Dr. K. Eric
Drexler, who promoted the technological significance of nano-scale
phenomena and devices through speeches and the books Engines of
Creation: The Coming Era of Nanotechnology (1986) and Nanosystems:
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Molecular Machinery, Manufacturing, and Computation (1991). Dexter
expanded the term nanotechnology giving it a more practical and
applicative sense, indicating nanotechnology as a broad range of
science and technology working at the length scale of approximately 1
to 100 nanometers, including the more specific goal it originally
denoted (Figure 1.1). Nanotechnology and nanoscience got started in
the early 1980s with two major developments: the birth of cluster
science and the invention of the scanning tunneling microscope
(STM). This development led to the discovery of fullerenes in 1985
and carbon nanotubes a few years later. In another development, the
synthesis and properties of semiconductor nanocrystals were studied;
this led to a fast increasing number of metal and metal oxide
nanoparticles and quantum dots.
Figure 1.1 The Nanometer Scale: the size comparison of nanoparticles with
biological objects
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Generally Nanotechnology deals with structures sized between 1 and
100 nm, also are sometimes included materials smaller than 1 µm.
Current nanotechnology progresses in chemistry, physics, materials
science and biotechnology have created novel materials that have
unique properties because their structures are determined on the
nanometer scale. Some of these materials have already found their
ways into consumer products, such as sun-screen, bathroom or
windows cleaner and stain-resistant paints. Others are being
intensively researched for solutions to humanity's greatest problems,
i.e. diseases, clean energy, clean water, land and air etc.
Other works are aimed by the desire to develop nano-electronic
devices and computer chips capable to store a large amount of
information in smaller and smaller space.
The products of advanced nanotechnology that will become available
in coming decades promise even more revolutionary applications than
the products of current and near-term nanotechnology.
Nanotechnology has also found important applications in the area of
healthcare and disease diagnosis and treatment, giving rise to the
specific branch of Nanomedicine.
1.1.1 Nanomedicine
Nanomedicine has been an important part of nanotechnology from
the very beginning and it is based on molecular knowledge of the
human body and the involvement of molecular tools for the diagnosis
and treatment of disease (Nanomedicine, www.nanobio-raise.org).
Living organisms are built of cells that are typically 10 µm across.
However, the cell parts are much smaller and are in the sub-micron
size domain. Even smaller are the proteins with a typical size of just 5
nm, which is comparable with the dimensions of the smallest
manmade nanoparticles.
This simple size comparison gives an idea of using nanoparticles as
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very small probes that would allow us to spy at the cellular
machinery without introducing too much interference. Understanding
of biological processes on the nanoscale level is a strong driving force
behind development of nanotechnology.
Today artificial bone implants already benefit from nanotechnological
materials, nanostructures surfaces are used for controlled tissue-
growth10,11, antibacterial surfaces incorporating photocatalytic or
biocidal nanoparticles12 have reduced the risk of infections. Moreover,
all kinds of medical devices profit from the miniaturization of
electronic components as they move beyond micro to nano.
Nanoparticulate pharmaceutical agents can penetrate cells more
effectively and, stimulated from outside the body, they can destroy
the tumor cells. New contrast agents (MRI, Magnetic Resonance
Imaging) and visualization tools provide a closer look at cellular
processes by using nanoparticles13. Portable testing kits allow for
self-monitoring and speedy diagnosis14. Nanoparticles can be used for
separation and purification of biological molecules and cells or for
protein detection15,16.
These are only some examples of nanomaterial applications to
medicine and biology, and many others can be found in various
reports on the prospects and promises of nanomedicine.
As mentioned above, the fact that nanoparticles exist in the same size
domain as proteins makes nanomaterials suitable for biomedical
applications. However, size is just one of the many characteristics
that itself is rarely sufficient for their medical use. Generally, a
biological or molecular layer acting as bioinorganic and inert interface
is required for nanoparticle coatings, such as polymers, lipids, gel or
silica, in a way to have biocompatible and stable particles.
The distribution of nanoparticles and their loads throughout the body
depends on many physico-chemical factors: size, toxicity, surface
charge, capacity for protein adsorption, drug loading and release
kinetics, stability, degeneration of carrier systems, hydration
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behaviour, electrophoretic mobility, porosity, surface characteristics,
density and molecular weight. The increase of therapeutic index, that
is the margin between the doses resulting in a therapeutic efficacy
(i.e. tumor cell death) and toxicity to the other organs of the body, is
needed for the preparation of long-lived and target-specific
nanoparticles17: in fact, one of the problems in the use of particulate
drug carriers is their entrapment in the reticuloendothelial system
(RES), mainly in the liver and spleen, which can drastically reduce
the time of permanence in the bloodstream18,19. Circulating
mononuclear phagocytes (monocytes) clear the nanoparticles to the
liver, spleen and bone where residence cells (e.g. Kupffer cells in the
liver) capture and expel nanoparticles by feces. Smaller nanoparticles
(< 50 nm) may be filtered by the kidneys and subject to rapid renal
elimination, while larger ones (> 200 nm) can be removed by
macrophages or dendritic cells. In general, the larger the particles
are, the shorter their plasma half-life-period is. According to their size
and their composition, different nanoparticle systems are used to
target specific area of the body, as reported in the scheme in Figure
1.2. In addition, surface coatings play an essential role in retarding
clearance by the RES. The most widely used coating for this purpose
is PEG (polyethylene glycol) that inhibits recognition and
phagocytosis by the RES because of its protein-resistant character.
However, the “immunostealthing” function provided by PEG is
frequently concurrent with the loss of biomolecular targeting
capabilities. The nature of the coating is also important where the
surface functionalization might cause hydrogen bonding and
agglomeration of nanoparticles, reducing their stability in body fluids.
Nevertheless, the fate and the toxicity of nanoparticles also depend
strongly on the dose and administration route (oral, intravenous,
pulmonary, transdermal, ocular).
1- Introduction
____________________________________________________________________
7
Figure 1.2. Nanoparticle systems for drug delivery applications and their
biodistribution.
1.1.2 Magnetic nanoparticles for biomedical
applications
The history of magnetism in medicine is old and is punctuated with
amazing anecdotes about the pioneering work of physicians (U.
Hafeli, Magnetism in medicine: A handbook, 1998). The first medical
uses of magnetite powder were reported by Egyptians in the 10th
century A.D. The magnetite was believed to render inert the
poisonous iron by attracting it and speeding up its excretion. More
recently, miniaturization of electromagnets, development of
superconducting electromagnets and introduction of permanent
magnets (Sm-Co and Nd-Fe-B) have stimulated the medical use of
magnets in different fields (cardiology, oncology, radiology). In
particular magnetic particles have found numerous medical
applications, see the scheme in Figure 1.3, thanks to their small size
and to their magnetic properties: in fact, the ability to distally control
the position of particles in a given media to induce their
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accumulation or separation from similar structures has found a
spectrum of powerful applications in innovative medicines20.
Generally, magnetic iron oxide nanoparticles are used because their
low toxicity and their suitability for in vivo applications: in fact, iron-
based particles do not cause oxidative stress or long-term changes in
the levels of liver enzymes in rat models (an indicator of biosafety),
and indeed good tolerances to high doses of such materials have been
reported21.
Figure 1.3. Magnetic nanoparticles applications in medicine
Although these iron-based materials are often referred to as
“magnetic”, the more accurate term “superparamagnetic” designates
their ability to become magnetized upon exposure to a magnetic field
but have no permanent magnetization (remanence) once the field is
turned off. In addition, the application of inorganic or polymeric
coating layers to magnetic particles minimizes hydrophobic
interactions, thus enhancing desirable properties, such as colloid
dispersion and biocompatibility (Figure 1.4). Strategies for the
preparation of magnetic particles and their surface coating have been
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recently summarized8 and widely discussed in Chapter 3 about Drug-
carriers preparation.
Figure 1.4. Architecture of magnetic particles (a) comprise the magnetic core (blue)
usually made of ferromagnetic magnetite, and a polymeric coating layer (green).
Depending on the intended function, additional elements can be incorporated,
including antibodies (pale blue), drugs (black), imaging agents (yellow) or diverse
chemical groups for specific or unspecific ligand binding (red).
The main applications of magnetic nanoparticles in medicine have
been reported and described in the following paragraphs.
Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) is one of the most powerful non-
invasive imaging modalities utilized in clinical medicine today. MRI is
based on the property that hydrogen protons will align and process
around an applied magnetic field, B0. Upon application of a
transverse radiofrequency (rf) pulse, these protons are perturbed
from B0. The subsequent process through which these protons return
to their original state is referred to as the relaxation phenomenon.
Two independent processes, longitudinal relaxation (T1-recovery) and
transverse relaxation (T2-decay), can be monitored to generate an
MRI. Local variation in relaxation, corresponding to image contrast,
arises from proton density as well as the chemical and physical
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nature of the tissues within the specimen.
Upon accumulation in tissues, magnetic nanoparticles provide
magnetic resonance contrast enhancement (i.e., changes in signal
intensity) by shortening both the longitudinal and transverse
relaxation of surrounding protons. However, T1 shortening processes
require a close interaction between protons and T1-agents, which can
be hindered by the thickness of the coating on the magnetic
nanoparticles (MNP). The effect of MNP on T2 shortening is caused by
the large susceptibility difference between the particles and
surrounding medium resulting in microscopic magnetic field
gradients. As described above, we can state that the effectiveness of a
contrast agent can be described by its relaxivity, which is the
proportionality constant of the measured rate of relaxation, or R1
(1/T1) and R2 (1/T2), over a range of contrast agent concentrations.
The relaxivity of a sample is affected not only by the magnetic
properties of the contrast agent, but also by experimental variables
such as field strength, temperature, and the medium in which the
measurements are made.
Some SPIO (superparamagnetic iron oxide nanoparticles) as bowel
contrast agents (i.e., Lumiren® and Gastromark®) and liver/spleen
imaging (i.e., Endorem® and Feridex IV®) are already on the market22.
Several forms of ultrasmall superparamagnetic iron oxides (USPIO)
have undergone clinical trials with one of the most notable being
Combidex® which is in late stage clinical trials for use in the
detection of lymph node metastases23.
Molecular imaging has been defined as the non-invasive in vivo visual
representation, characterization, and quantification of biological
processes at the cellular and molecular levels. For instance,
molecular imaging allows sensitive and specific monitoring of key
molecular targets and host responses associated with early events in
carcinogenesis. By coupling advances in medical imaging technology
with those in molecular and cell biology, this growing research
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discipline offers the potential to have a major impact on early disease
detection, individualized treatment, and drug development. Due to
their ability to serve as molecularly targeted imaging agents, MNP are
now and will continue to play an integral role in this developing field.
Bioseparation and protein purification
The isolation of molecules, proteins and nucleic acids from natural
samples requires that these macromolecules are separated from
complex samples to be highly purified. Furthermore, emerging
medical applications require the isolation of specific cell types from
human samples, or alternatively, the depletion of undesired types
from clinical material, such as the removal of cancer cells. These
objectives can be achieved with the use of magnetically controlled
particles, thus skipping the multiple-step approaches of conventional
separation approaches.
Chromatographic protein purifications provide high-resolution
separations, but these methods cannot handle “dirty” samples
because colloidal contaminants frequently plug the packed-bed
columns. By contrast, functionalized MNP allow for quick and
efficient purification, eliminating the need for most of the pre-
treatment steps, including centrifugation, filtration and membrane
separation (Figure 1.5). To achieve this, magnetic particles can be
decorated either with specificity ligands or with specific recognition
groups, including monoclonal or polyclonal antibodies.
Among the existing protocols, magnetic separation and purification is
a convenient method for selective and reliable capture of specific
proteins, genetic materials, organelles and cells24. The high surface-
to-volume ratio and the good dispersity of the nanoparticles also
increase the protein binding capacity. The specificity of the MNP
exhibited in protein separation suggests that MNP, as a general and
versatile system, should selectively bind with other biological targets
at low concentrations if proper anchors and ligands are used.
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Figure 1.5. Schematic representation of magnetically driven separations (a) Target
macromolecular species, usually proteins or nucleic acids (blue spheres), can be
separated from potentially similar molecular species (green and orange symbols) by
magnetic particles (gray spheres) that have been functionalized with specific
ligands. After washing and elution, the target molecule can be recovered. (b) In
magnetically assisted cell sorting (MACS), specific cell types are isolated from
complex samples. Magnetic particles (gray spheres) are functionalized with ligands
of surface receptors present in a single cell type (here in the blue cells), which
permits their separation in a chromatographic column to which a magnet has been
applied.
Tissue engineering
Tissue engineering exploits biology and engineering principles for the
development of functional substitutes of lost or damaged tissues.
Typically, tissue engineering has been based on the expansion of cells
in vitro before seeding them onto three-dimensional (3D)
biodegradable scaffolds to mimic their native organization and
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differentiation, followed by the introduction of the colonized scaffold
into the cell donor. An emerging tissue engineering strategy, so-called
“magnetic-force based tissue engineering” (Mag-TE), employs cells that
have been magnetically labeled with magnetoliposomes (liposomes
embedded with MNP) which might also be further modified with
integrin-binding peptides to facilitate cellular uptake.
Magnetoliposomes labelled-cells can then be organized by magnetic
force, as shown in Figure 1.6a25.
Figure 1.6. Magnetic particles in tissue engineering. (a) Different cell types
(in purple and blue) are separately labeled by magnetoliposomes and
sequentially seeded onto an ultra-low attachment plate under which a
magnet is placed. This leads to the generation of 3D multilayered cell sheets
by magnetic-force-based tissue engineering (Mag-TE). Removal of the
magnet allows the recovery of the construct for use. (b) Tubular structures
can be generated by folding preformed cell layers, obtained as shown in
panel (a), around rod-shaped magnetic models. Such tubular constructs are
recovered after removal of the magnet.
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In this approach, a magnet is applied to the underside of ultra-low-
attachment well plates, which attract and accumulate magnetically
labeled cells. In this way, populations of magnetoliposome-labeled
cells can be sequentially driven to the surface to create 2D patterned
or even 3D multilayered structures25,26.
Tubular structures have also been created using the Mag-TE method.
In this approach, magnetically labeled cells formed a cell sheet onto
which a cylindrical magnet was rolled, which was removed after the
tubular structure had been formed (Figure 1.6b).
Drug delivery and gene delivery (transfection)
One of the most promising applications of nanotechnology in
medicine is drug delivery, which has the purpose to deliver
pharmaceutical agents directly to a specific site of the body, i.e.
disease or cancer cells. The development of drug delivery started with
the idea of Paul Ehrlich (1854-1915), who proposed the use of a
“magic bullet” capable to target specificity disease cells in the body.
The concept of using magnetic micro and nano-particles for drug
delivery was proposed in the late 1970s by Widder et al, who
described the targeting of magnetic albumin microsphere
encapsulating an anticancer drug (doxorubicin) in animal models27.
Ideally, magnetic particles could bear on their surface or in their bulk
a pharmaceutical drug that could be easily directed to a specific site
of the body by an external magnetic force, and once they have
reached the target organ, they can release the bounded bioactive
molecules. As result, a functional magnetic drug carrier consists of: a
magnetic core, a protective coating and an active drug (chemo or
radio-therapeutic agents). Analogously, magnetic nanoparticles could
be use for gene delivery or magnetofection: in fact, magnetic particles
associated with vector DNA could be transfected into cells by the
influence of an external magnetic field. Generally high magnetic fields
and high gradients are required to allow the particles to target the
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specific site. While this may be effective for targets close to the body’s
surface, as the magnetic field strength falls off rapidly with distance,
sites deeper within the body become more difficult to reach. For this
reason some groups have recently proposed a way around this
problem by implanting magnets near a target site, within the
body28,29.
The development of magnetically controlled drug release is due to the
limitations of conventional treatments, including surgery, radiation,
chemotherapy and biologic therapy (immunotherapy); i.e., because of
their difficult accessibility to the tumor, the risk of operating on a
vital organ, the spread of cancer cells throughout the body, and the
lack of selectivity toward cancer cells.
The potential advantages of drug delivery systems based on the use of
nano and micro-particles are:
• The ability to target specific location of the body
• The reduction of the quantity of drug needed to attain a
particular concentration in the vicinity of the target
• The reduction of the drug concentration at non-target sites
minimizing severe side effects
• Reduction in toxicity while maintaining therapeutic effects
The reason why nanoparticles are attractive for biomedical purposes
is based on their high surface to mass ratio, their possibility to be
functionalized and their ability to adsorb and carry other compounds.
Generally, relatively large vectors (size > 100 nm) may be needed for
loading larger amounts of drugs and the material of their composition
may be of biological origin like phospholipids, lactic acid, dextran,
chitosan, or may have more “chemical” characteristics like polymers,
carbon, silica and surfactants30. The main characteristics that
nanoparticles should have are biocompatibility, biodegradability and
stability in order to prevent aggregation or toxicity.
Vectors sensitive to physical stimuli have been developed and
conjugated to drugs. Nanoparticles must be endowed with specific
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characteristics needed to reach a specific target, which means
attaining a suitable combination of nature, size, way of drug
conjugation (adsorbtion, encapsulation, attachment), and physical
response properties at different external stimuli. Recently, the most
common methods to favor drug leakage from nanoparticle-carriers
(polymer, gel, liposomes) are based on the destabilization of the
system by an external stimulus such as pH changes31, temperature
increase (hyperthemia)32-35, magnetic exposure36,37, ultrasounds
application38,39 and ionic strength changes40.
Magnetically mediated hyperthermia is a particular application of
magnetic nanoparticles in drug delivery (Figure 1.7a). Magnetite
particles exposed to an external alternating magnetic field (AMF) are
heated through either hysteresis loss or relaxation loss depending on
their size and properties. Because cancer cells are killed at
temperature over 44°C, whereas normal cells survive at these higher
temperatures, magnetically mediated hyperthermia induced by AMF
can be used to selectively destroy cancer cells in which magnetic
particles have been accumulated (Figure 1.7b).
Nucleic acid transfer and gene therapy have been areas of intense
research in recent years due to their potential to generate a
significant impact in medicine. However, the delivery of genes and
their resulting transfections efficiency are often limited by their short
half-life in vivo, lack of specificity and poor diffusion across cell
membranes. The use of MNP as carriers for DNA or gene vectors
overcomes many of the problems associated with the delivery of these
therapeutic agents. Magnetofection, the magnetically enhanced
nucleic acid delivery method, uses magnetic force to direct nucleic
acids attached to magnetic nanoparticles towards and into target
cells (by placing a magnet under the cell culture plate41.
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Figure 1.7. In vivo therapeutic applications of distally controlled magnetic
nanoparticles. (a) Magnetic particles (gray spheres) associated to therapeutic
molecules (shown as orange spheres) act as vehicles for drug delivery, and after
systemic administration they are concentrated to the target organ (O) with the help
of a magnet (M). (b) In magnetically mediated hyperthermia (MMH), systemically
administered magnetic particles (gray spheres) accumulate in a tumor (T). Particles
in the tumor are then heated (illustrated by the change to red spheres) through the
external application of an alternating magnetic field (AMF), and this results in the
death of the tumor cells.
As described above, an external magnetic field is generally required
for MNP applications in biomedicine. Although all the components of
the body are either dia-, para-, superpara-, ferri- or ferromagnetic,
the magnetic fields must be very large. Even red blood cells, which
each contains micrograms of the Fe protein haemoglobin, show a
relatively low response to large fields or field gradients. Many studies
have shown that also magnetic field of 10 T could be achieved for
human imaging42. However, strong static magnetic field of 8 T have
shown to reduce the flow rate of human blood by 30% in vitro tests
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and it has been reported that magnetic fields above 3 T might effect
the normal behaviour of erythrocytes43.
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1.2  Magnetic Nanoparticles
Magnetic nanoparticles (MNP) are of great interest for researchers
from a wide range of disciplines, as described above. In most of the
envisaged applications, the particles perform best when the size of
the nanoparticles is below a critical value, which is dependent on the
material, but is typically around 10–20 nm. Then each nanoparticle
becomes a single magnetic domain and shows superparamagnetic
behaviour when the temperature is above the so-called blocking
temperature. Such individual nanoparticles have a large constant
magnetic moment and behave like a giant paramagnetic atom with a
fast response to applied magnetic fields with negligible remanence
(residual magnetism) and coercivity (the field required to bring the
magnetization to zero). These features make superparamagnetic
nanoparticles very attractive for a broad range of biomedical
applications because the risk of forming agglomerates is negligible at
room temperature.
However, an unavoidable problem associated with particles in this
size range is their intrinsic instability over longer periods of time.
Such small particles tend to form agglomerates to reduce the energy
associated with the high surface area to volume ratio of the nanosized
particles. Moreover, naked metallic nanoparticles are chemically
highly active, and are easily oxidized in air, resulting generally in loss
of magnetism and dispersibility.
For many applications it is thus crucial to develop protection
strategies to chemically stabilize the naked magnetic nanoparticles
against degradation during or after the synthesis. These strategies
comprise grafting of or coating with organic species, including
surfactants or polymers, or coating with an inorganic layer, such as
silica, citrate or oleic acid.
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A brief description of magnetism and magnetic properties of materials
is reported below to better understand the magnetic behaviour of
superparamagnetic nanoparticles.
1.2.1 Magnetic properties of nanoparticles
Magnetism is the result of charge movements, and therefore the
magnetic properties of matter are related to both the orbital and spin
motions of electrons. Other contributions, such as nuclear magnetic
moment, are usually negligible. Depending on the electronic
structure, materials are characterized by different magnetic
properties and different interactions with external magnetic fields.
The magnetic susceptibility, χ, is an estimate of the magnetization M
response to an external magnetic field H and it is defined as χ = δM /
δH.
Diamagnetism appears in all materials, and is the tendency of a
material to oppose an applied magnetic field, and therefore, to be
repelled by a magnetic field.
In a diamagnetic material, there are no unpaired electrons, so the
intrinsic electron magnetic moments cannot produce any bulk effect.
Paramagnetism appears when materials have unpaired electrons, so
that an external magnetic field induces a net magnetization, which is
not preserved after the external magnetic field removal.
Ferromagnetism appears when materials possess all unpaired
electrons, and therefore a high magnetic susceptibility.
Ferromagnetic materials are permanent magnets and they remain
magnetized even after a magnetic field removal.
Superparamagnetism is a form of magnetism, which appears in
small ferromagnetic nanoparticles. In small enough nanoparticles,
magnetization can randomly flip direction under the influence of
temperature. Two key issues dominate the magnetic properties of
nanoparticles: finite-size effects and surface effects. In large magnetic
particles, it is well known that there is a multi-domain structure,
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where regions of uniform magnetization are separated by domain-
walls. If the sample size is reduced, there is a critical volume below
which it costs more energy to create a domain wall than to support
the external magnetostatic energy of the single-domain state. This
critical diameter typically lies in the range of a few tens of
nanometers and depends on the material. A single-domain particle is
uniformly magnetized with all the spins aligned in the same direction.
The magnetic anisotropy per particle, which is responsible for holding
the magnetic moments along a certain direction, is proportional to
the energy barrier (KV, where K is the anisotropy constant and V the
particle volume) between two energetically equivalent easy directions
of magnetization. With decreasing particle size, the thermal energy,
kBT, exceeds the energy barrier and the magnetization is easily
flipped. For kBT>KV the system behaves like a paramagnet and the
system is named superparamagnet because of the presence of a
single giant moment inside each particle44.
Normally, any ferromagnetic material undergoes a transition to a
paramagnetic state above its Curie temperature, which is the
temperature at which a ferromagnetic material becomes
paramagnetic on heating.
Superparamagnetism is different from this standard transition since
it occurs below the Curie temperature of the material.
Superparamagnetism occurs in nanoparticles composed of a single
magnetic domain. This is possible when their diameter is below  a
critical diameter, which depends on the materials and the shape. In
this condition, it is considered that the magnetization of the
nanoparticles is a single giant magnetic moment (one magnetic
domain), sum of all the individual magnetic moments carried by the
atoms of the nanoparticle. In this state, there is a finite probability
for the magnetization (the giant moment) of the nanoparticle to flip
and reverse its direction. The global relaxation rate of the magnetic
colloid is the sum of two different contributions: the Néel relaxation
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and the Brown relaxation.
The Néel relaxation time, τN, is given by the following Néel-Arrhenius
equation:
€ 
τN = τ 0 exp
KV
kBT
 
 
 
 
 
                                                                         (1.1)
where:
• τN is the average length of time that it takes for the
nanoparticle magnetization to randomly flip as a result of
thermal fluctuations.
• τ0 is a length of time, characteristic of the material, called the
attempt time or attempt period; its typical value is 10-9 second.
• K is the nanoparticle magnetic anisotropy and V its volume. KV
can be thought of as the energy barrier associated with the
magnetization moving from its initial "easy axis" direction,
through a "hard axis", ending at another easy axis.
• kB is the Boltzmann constant.
• T is the temperature.
This length of time can be anywhere from a few nanoseconds to years
or much longer. In particular, it can be seen that the Néel relaxation
time is a function of the exponential of the grain volume, which
explains why the flipping probability becomes rapidly negligible for
bulk materials or large nanoparticles.
The Brown relaxation (τB) is the viscous rotation of the entire
nanoparticle and is given by the following equation:
€ 
τB =
3Vη
kT                                                                                    (1.2)
where V is the volume of the particle, η is the viscosity of the solvent,
k is the Boltzman constant and T the temperature.
Nèel and Brown relaxations are schematized in Figure 1.8.
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Figure 1.8. Illustration of the two components of the magnetic relaxion of a
magnetic fluid.
If the magnetization of a single superparamagnetic nanoparticle could
be measured, and τm considered the measurement time, τm could be
compared to τN. If τm >>τN, the nanoparticle magnetization will flip
several times during the measurement so the magnetization
measured will be zero. If τm << τN, its magnetization will not flip
during the measurement so the magnetization measured will be the
magnetic moment carried by the nanoparticle. In the first case, the
nanoparticle will appear to be in the superparamagnetic state
whereas in the second case it will appear to be ferromagnetic. The
state of the nanoparticle (superparamagnetic or ferromagnetic)
depends on the measurement time. In several experiments, the
measurement time is kept constant but the temperature is varied so
the transition between superparamagnetism and ferromagnetism is
seen as a function of the temperature. The temperature for which τm
= τ N is called the blocking temperature because, below this
temperature, the magnetization is seen "blocked" on the time scale of
the measurement.
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1.3 Lipid vesicles
Lipid vesicles are hollow microspheres, formed by self-assembly in
water of phospholipids. Their membrane consists of one or more lipid
bilayers, which entrap the aqueous medium in which they are
suspended.
Lipid vesicles can be classified in function of their size and physical
structure. Multilamellar lipid vesicles (MLV) are usually larger than
500 nm and consist of several concentric bilayers; unilamellar
vesicles, formed by a single bilayer, are classified as: small (SUV)
when size range between 20 and 100 nm, large (LUV) when diameter
range from 100 nm to 1 µm, and giant (GUV) when they are larger
than 1 µm (Figure 1.9).
Figure 1.9. Molecular shape of lipids and vesicle classification
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Because of the amphiphilic character of the phospholipids, liposomes
can encapsulate both hydrophobic molecules in the bilayer
membrane and hydrophilic molecules in the aqueous internal pool.
These properties have led to a lot of applications of lipid vesicles as
models for biological membranes, as drug delivery vectors for in vivo
applications and for gene-therapy. Drugs, vaccines, DNA, antibodies
and other molecules can interact with liposomes in several different
ways depending on their chemical and physical properties. They can
be inserted in the lipid chain bilayer region, intercalated in the polar
head group region, adsorbed on the membrane surface, anchored by
hydrophobic tail or entrapped in the inner aqueous pool. The large
use of liposomes for biomedical applications is related, in addition to
their amphiphilic properties, to their attractive biological properties:
- They are biocompatible
- Size, charge and surface properties can be easily changed by
adding new ingredients to the lipid mixture before liposomes
preparation and/or by variation of preparation methods.
- They protect pharmaceuticals from the inactivating effect of
external conditions.
- They can deliver pharmaceuticals into cells or even inside
individual cell compartments.
An important requisite for the use of liposomes as drug delivery
vehicles is to develop methods allowing to control liposome
preparation, including particle size, stability, encapsulation rates and
to determine the leakage kinetics of the entrapped substances.
In order to better understand liposome behaviour, some general
features of amphiphiles and phospholipids are presented below.
1.3.1 Amphiphiles and phospholipids
Amphiphiles, also referred to as surfactants, are molecules that
contain both hydrophobic (non-polar tail) and hydrophilic (polar
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head) part. Because of this dual character and the energetically
unfavourable contact between the non-polar part and water,
amphiphiles spontaneously aggregate. There is a wide variability of
aggregates of different sizes and geometries depending on both
hydrophobic tail and polar head properties. The tail length, consisting
of multiple chains, the polar head charge and size, temperature, pH
and concentration influence the geometry of the aggregate.
Figure 1.10. The surfactant parameter S and the corresponding geometrical
packing of amphiphilic molecules. L: micellar solution, H: hexagonal phase, Lα:
lamellar phase. Subscripts I and II denote normal and reversed phase, respectively.
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A surfactant parameter, S, contains information about the
geometrical shape and curvature of the aggregate obtained from a
certain surfactant.
The surfactant parameter, S, is defined by 
€ 
S = νla0
, where ν stands for
the volume of the hydrophobic portion, l, is the length of the
hydrocarbon chains and ao is the effective area per head group. The
value of S relates the properties of the molecule to the mean
curvature of the formed aggregates. By convention the curvature is
positive (micelles) if the aggregate is curved around the hydrophobic
part and negative (reversed micelles) if it is curved towards the polar
part. The relationship between the value of the surfactant parameter
and the optimal aggregate structure is shown in Figure 1.10.
Although the surfactant parameter can only be considered to be a
crude and approximate model for predicting self-assembly, it provides
valuable insight into how changes of molecular structure affect the
shape of the formed aggregate.
A class of amphiphilic molecules is phospholipids, which are the
major component of all cell membranes in the form of lipid bilayer. A
phospholipid has two acyl chains, usually consist of saturated or
unsaturated long fatty acids, linked to a head group (coline, serine,
ethanolamine) by means of a phosphoglycerol-backbone. Figure 1.11
shows the structural formula of a phospholipid. Phosphatidylcholines
or PC-lipids are the most widely used lipids in liposomes work. PC-
lipids are zwitterionic at all relevant pH and can therefore form
lamellar structures independently of the pH in the solution.
Phospholipid lamellar phases may exist in different physical states in
function of temperature and lipid composition. Low temperature or a
high degree of saturation forces the bilayer into a gel state, in which
hydrocarbon chains exhibit close packing and more or less frozen
conformation.  Increasing the temperature or introducing
unsaturated acyl chains results in a bilayer of a liquid crystalline
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state, where the chains are disordered and have high mobility. The
temperature at which the gel-to-liquid crystalline phase transition
occurs is the melting temperature (Tm). Comparing an unsaturated
phospholipid with the saturated analogue, the Tm of the last one will
be significantly higher.
Figure 1.11. Structure of a phospholipid (in this case phosphatidylcholine).
The molecular geometry of most phospholipids can be approximated
as cylinders and according to the geometrical packing concept, they
prefer to self-assemble into bilayers. The formation of liposomes from
bilayer structures by self-closing is in competition with the bending
(curavature energy) and the edge energy of a bilayer.
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Figure 1.12. Liposome formation
The bilayer bending can reduce the edge energy, and when the
increase of the curvature lead to a closed sphere, the edge energy is
reduced to zero, while the bending energy is at its maximum.
Generally larger liposomes are energetically favoured. A scheme of the
liposome formation is reported in Figure 1.12.
1.3.2 Stability and applications of liposomes
The nature of lipids and the special properties of liposomes have
generated many applications in medicine, in particular they have
found application as vaccine and drug carriers, model membranes
and in cell physiology studies.
Liposome use in drug delivery depends on their physicochemical
properties (i.e. size, surface charge) and on their biological
interactions with the cells. Biological stability includes control over
the rate of clearance of liposomes from circulatory system or
compartments of the body. The rate of clearance is dose-dependent
and varies according to the size and surface charge of the liposomes.
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In addition, biological stability also comprises retention of the drug
by the carrier en route to its destination (sustained release). For
example, lipoproteins in the plasma were found to remove
phospholipids rapidly from the bilayers of the vesicles, leading to
their disintegration and premature drug loss. Moreover lipids, like
most biomolecules, undergo different degradation processes and the
most common are oxidation and hydrolysis. In the case of
phosphatidylcholine, which is the most commonly used lipid in
medicine applications, the hydrocarbon chains and especially the
unsaturated ones are subject to oxidation. The oxidation is a radical
reaction, which finally results in the cleavage of the hydrocarbon
chains or in the formation of cyclic peroxides. The use of lipids with
high purity, the protection from light and oxygen, and the storage at
low temperature can minimize lipid oxidation.
The ester bonds present in phospholipids may be subject to
hydrolysis in water, in particular the carboxyl esters are hydrolysed
faster than the phosphate esters. The hydrolysis rate is both pH and
temperature dependent, and by selecting low temperature and
neutral pH the hydrolysis can be largely avoided.
However oxidation and hydrolysis of liposomes occur, in vivo,
concomitant with their interaction with blood components. An
approach to avoid lipid degradation and to prolonging the circulation
time of liposomes involves making their surface highly hydrophilic by
covalently attaching polymers or PEG to them.
Liposomes functionalized with cell-specific ligands can be loaded with
different drugs in order to promote cell recognition and transport the
drug to a specific target17,45 minimizing the distribution of drugs to
non-targeted tissues. Drug molecules can interact with liposomes in
several different ways depending on the drug’s solubility and polarity
characteristics. Water-soluble drugs are usually entrapped into the
aqueous pool, while water-insoluble drugs can be solubilized in the
hydrophobic bilayer of liposomes. Hydrophilic drugs are most simply
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encapsulated automatically upon hydration of the lipids with a
corresponding drug solution. Hydrophobic drugs are generally mixed
with the lipid solution in an organic solvent and entrapped in the
lipid bilayer during the formation of phospholipid films. The non-
encapsulated drug molecules can be then removed by size exclusion
chromatography (SEC) or dialysis. Once drug-loaded liposomes have
reached the target site, the drug must to be released with an efficient
rate. This can be obtained through the destabilization of the delivery
system by an external stimulus, followed by the leakage of the drug.
On this basis, although trans-membrane diffusion of the embedded
drug takes place spontaneously in liposomes, in many cases a
controlled, fast and complete release of the drug is required.
Many factors have been shown to affect liposome permeability46, such
as a temperature increase especially when close to the lipid melting
temperature (Tm)47, the doping with large headgroup amphiphiles48,
etc. In general, the permeability is correlated to the lateral
compressibility consistently with the formation of defects and/or
pores promoting the diffusion. Enhanced drug release has been
achieved by using pH-sensitive lipids31, by stimulating temperature-
sensitive liposomes via local hyperthermia32,36, and by mechanical
disruption with low frequency ultrasounds38,39.
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1.4 The project aim
Aim of this project is to study the effect of a low-frequency magnetic
field (LF-AMF) on the permeability and release properties of magnetic
nanoparticles-embedded liposomes (magnetoliposomes). Large (LUVs)
and giant (GUVs) unilamellar vesicles loaded with three different
Cobalt Ferrite Nanoparticles (CoFe2O4 NPs): uncoated, citrate and
oleic acid coated Nps were prepared and characterized. The
hydrophilic nanoparticles (uncoated and citrate coated NPs) were
embedded in the aqueous pool of liposomes, while the hydrophobic
ones (coated with oleic acid) were entrapped in the lipid bilayer of
liposomes. According to their sub-micrometer diameter, LUVs or
liposomes are used for in vivo applications, while GUVs are used as
cellular models to study membrane perturbations in the presence of
an external stimulus49,50.
A number of investigations have been reported on exploiting
superparamagnetic NPs in targeted and controlled release of
drugs33,37,51: in fact, magnetic NPs can be efficiently encapsulated
inside lipid vesicles and used for targeting a specific location of the
body by an external magnetic force9. A way to promote drug release
and to tune magnetoliposome permeability is the application of an
alternating magnetic field. In most cases a high-frequency alternating
magnetic field  (HF-AMF) was used to promote local heating, or
magnetic fluid hyperthermia (MFH) of Nps, which are located in the
targeted tumor cells, causing their thermal ablation without
damaging the healthy tissues36. In this thesis, for the first time, a low
frequency alternating magnetic field (LF-AMF, frequency < 10 kHz)
was used in order to minimize the temperature contribution and
investigate mainly the field effect. Cobalt Ferrite NPs were produced
introducing some modifications to the method originally proposed by
Massart (see Methods and Drug-carriers) and they were then used to
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load the pool of lipid vesicles. The increase of magnetoliposome
permeability upon exposure to LF-AMF was evaluated as the self-
quenching decrease of the fluorescent molecule Carboxyfluorescein
(CF) entrapped in the liposome pool. Liposome leakage was monitored
as a function of field frequency, time of exposure, size, charge,
concentration and different coatings of NPs. To gain further
knowledge into the leakage mechanism induced by LF-AMF, Confocal
Laser Sanning Microscopy (CLSM) experiments were performed on
magnetic GUVs labeled with the fluorescent probe DiIC18 and filled
with the water-soluble fluorescent dye Alexa 488-maleimide.
Moreover fluorescent and magnetic particles were also prepared and
used as a system for locating their position in GUVs and to study the
effect of a LF-AMF on the permeability of magnetic vesicles by
Confocal Laser Scanning Microscopy (CLSM). Silica-coated Cobalt
ferrite nanoparticles incorporating Rhodamine B isothiocyanate
MP@SiO2(RITC) were synthesized by a sol-gel method52-54 and
incorporated on GUVs.  Drug release experiments were carried out by
CLSM-time series acquisition, measuring the change in fluorescence
intensity of the Alexa 488-C5-maleimide fluorescent dye loaded in the
aqueous pool of GUVs, in order to check the vesicle permeability
changes or their structure deformations during and after the LF-AMF
exposure.
Figure 1.13. Sketch of CoFe2O4 nanoparticles-embedded liposomes
containing carboxyfluorescein (CF) and subsequent CF release upon
application of low frequency alternating magnetic field (LF-AMF).
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2 - Methods
2.1 Syntheses of magnetic nanoparticles
Numerous chemical methods can be used to synthesize magnetic
nanoparticles: co-precipitation reactions, microemulsions, sol-gel
syntheses,  sonochemical reactions, hydrothermal and high-
temperature reactions, flow injection syntheses and electro-spray
syntheses1.
The first main chemical challenge consists of defining experimental
conditions, leading to a monodisperse population of magnetic grains
of suitable size. The second critical point is to select a reproducible
process that can be industrialized without any complex purification
procedure, such as ultracentrifugation, s i z e - e x c l u s i o n
chromatography or magnetic filtration. These methods have been
used to prepare particles with homogeneous composition and narrow
size distribution.
In this work Cobalt ferrite (CoFe2O4) NPs stabilized with different
coatings were prepared by co-precipitation and sol-gel methods. More
details about the syntheses were reported in Chapter 3 about Drug-
carriers preparation.
2.1.1 Synthesis by co-precipitation
The co-precipitation technique is probably the simplest and most
efficient chemical pathway to obtain magnetic particles.
Metal oxides, such as iron oxide (magnetite, Fe3O4) or Cobalt ferrite
(CoFe2O4), have found a high number of applications. Metal oxides
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are usually prepared by a stoichiometric mixture of metal salts in
aqueous medium, i.e. Fe3O4 nanoparticles are prepared by mixing
ferrous and ferric salt solutions.
The size, the shape and the composition of the nanoparticles depend
on the reaction temperature, the pH value and ionic strength of the
media.
The main advantage of the co-precipitation process is that a large
amount of nanoparticles can be synthesized. However, the control of
particle size distribution is limited, because mainly kinetic factors are
controlling the growth of the crystal: in fact, the co-precipitation
process consists of two stages, a short burst of nucleation followed by
a slow growth of the nuclei by diffusion of the solutes to the surface
of the crystal.
Nanoparticles prepared by co-precipitation unfortunately tend to be
rather polydisperse. It is well known that short burst nucleation and
subsequent slow controlled growth is crucial to produce
monodisperse nanoparticles. Controlling these processes is therefore
the key in the production of monodisperse metal oxide magnetic
nanoparticles. The addition of chelating anions (carboxylate ions,
such as citric, gluconic or oleic acid) or polymer surface complexing
agents (dextran or polyvinyl alcohol) during the formation of magnetic
cores can help to control the size of the nanoparticles. According to
the molar ratio between the organic ions and the iron salts, the
chelation of these organic ions on the metal oxide surface can either
prevent nucleation and then lead to larger particles or inhibit the
growth of the crystal nuclei, leading to small nanoparticles.
The first controlled preparation of superparamagnetic iron oxide
particles using alkaline precipitation of FeCl3 and FeCl2 was
performed by Massart2. The parameters of this process were carefully
studied to demonstrate the influence of the base (ammonia and
NaOH) of the pH value, of cations (N(CH3)4+, CH3NH3+,Na+, K+ and
NH4+)3 and the temperature effect4,5. When all of these parameters are
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modulated, it is possible to obtain particles with a size ranging from 2
to 20 nm. The shape variation is related to the variation of the
electrostatic surface density of the nanoparticles.
2.1.2 Synthesis in microemulsion
A microemulsion is a thermodynamically stable isotropic dispersion
of two immiscible liquids, where the microdomain of either or both
liquids is stabilized by an interfacial film of surfactant molecules6.
Surfactant molecules may spontaneously form nanodroplets of
different sizes, micelles (oil-in-water emulsions, 1-10 nm) or reverse
micelle (water-in-oil emulsions, 10-100 nm). Generally reverse micelle
are used as nanoreactors for nanoparticle synthesis. In particular,
the size of the reverse micelle is determined by the molar ratio of
water to surfactant7 and by the concentration of reactants. By mixing
two identical water-in-oil microemulsions containing the desired
reactants, the microdroplets will continuously collide, coalesce, and
break again, and finally a precipitate forms in the micelles8. By the
addition of a solvent, such as acetone or ethanol, to the
microemulsions, the precipitate can be extracted by filtering or
centrifuging the mixture. In this sense, a microemulsion can be used
as a nanoreactor for the formation of nanoparticles. The surfactant-
stabilized nanoreactor provides a confinement that limits particle
nucleation and growth. For this reason the main advantage of
microemulsion reaction is the possibility to control the nanoparticle
sizes.
Using the microemulsion technique, metal oxide MFe2O4 (M: Mn, Co,
Ni, Cu, Zn, Mg, or Cd, etc) nanoparticles have been synthesized in
reverse micelles of cetyl-trimethylammonium bromide (CTAB), using
1-butanol as co-surfactant and octane as the oil phase.
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2.1.3 Sol-Gel synthesis
The sol-gel process is a wet-chemical technique used for the
synthesis of nanostructured metal oxides9. In this process, the sol (or
solution) evolves gradually towards the formation of a gel-like
network containing both a liquid phase and a solid phase. Typical
precursors are metal alkoxides and metal chlorides, which undergo
hydrolysis and polycondensation reactions to form a colloid. The
basic structure or morphology of the solid phase can range anywhere
from discrete colloidal particles to continuous chain-like polymer
networks. The sol-gel approach is a cheap and low-temperature
technique that allows for the fine control of the product’s chemical
composition.
A typical sol-gel process is the hydrolysis of tetraethyl orthosilicate
(TEOS) that lead to the formation of SiO2 in the form of fibers. For
this reason, silica shells have been widely used to protect magnetic
cores, also preventing the direct contact of the magnetic core with
additional agents linked to the silica surface thus avoiding unwanted
interactions10,11. For instance, the direct attachment of dye molecules
to magnetic nanoparticles often results in luminescence quenching.
To avoid this problem, a silica shell was first coated on the magnetic
core, and then dye molecules were grafted on the silica shell12. Silica
coatings have several advantages arising from their stability under
aqueous conditions (at least if the pH value is sufficiently low), easy
surface modification, and easy control of interparticle interactions,
both in solution and within structures, through variation of the shell
thickness.
2.1.4 Hydrothermal and high temperature
synthesis
Hydrothermal syntheses are performed in reactors or autoclaves
where the pressure can be higher than 140 bar and the temperature
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can be above 200°C13. There are two main steps for the formation of
metal oxides nanoparticles: hydrolysis and oxidation or neutralization
of mixed metal hydroxides. This strategy is based on a general phase
transfer and separation mechanism occurring at the interfaces of the
liquid, solid and solution phases present during the synthesis. In this
process, the reaction conditions, such as solvent, temperature and
time have important effects on the products14. In the hydrothermal
process, the particle size in crystallization is controlled mainly
through the rate processes of nucleation and grain growth.
Nucleation might be faster than grain growth at higher temperatures
and results in a decrease in particle size. On the other hand,
prolonging the reaction time would favor grain growth.
Nanoparticles with a high level of monodispersity and size control can
be obtained by high temperature decomposition of iron organic
precursor in the presence of high boiling organic solvents and
stabilizing surfactants15.  The organometallic precursor include metal
acetylacetonates, (M(acac)n, where M = Fe, Mn, Co, Ni, Cr; n = 2 o 3;
acac = acetylacetonate), metal cupferronates (Mxcupx, where M=
metal ion; cup = N-nitrosophenylhydroxylamine) or carbonyls. Fatty
acids, oleic acid and hexadecylammine are often used as surfactants.
The size and the morphology of the nanoparticles can be controlled
by controlling the reaction times and the temperature, as well as the
concentration and ratios of the reactants, nature of the solvent,
precursors and complexing strength16.
2.1.5 Sonochemical and flow-injection syntheses
The sonolysis of aqueous solution of metal salts in the presence of
surfactants leads to the formation of stable hydrosol of amorphous
metal oxides nanoparticles17.
The flow-injection synthesis techinque (FIS) consisted of a continuos
or segmented mixing of reagents under a laminar flow regime in a
capillary reactor18. The FIS technique has a high reproducibility
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because of the laminar conditions of the flow, a high mixing
omogenity and the opportunity for precise and external control of the
process.
2.1.6 Stabilization of magnetic nanoparticles
The stabilization of the metal oxide nanoparticles is crucial to obtain
magnetic colloidal ferrofluids that are stable against aggregation in
both biological medium and a magnetic field. The stability of a
magnetic fluid results from the equilibrium between attractive and
repulsive forces. Theoretically electrostatic charges and steric
repulsion (in the case of non-naked nanoparticles) induce repulsive
forces, while van der Waals and magnetic dipolar forces induce,
respectively, strong short-range isotropic and anisotropic attractions.
Stabilization of magnetic nanoparticles can be achieved by playing on
one or both of the two repulsive forces: electrostatic and steric
repulsion (Figure 2.1).
Figure 2.1. (a) Nanoparticles stabilized by electrostatic repulsion; (b) nanoparticles
stabilized by steric repulsion.
The electrostatic repulsion can be followed through the knowledge of
the diffusion potential, that may close to the zeta potential, and the
ionic strength and pH of the solution. In iron oxide, the surface iron
atoms act as Lewis acids and coordinate with molecules that donate
lone-pair electrons. Therefore, in aqueous solutions, the Fe atoms
coordinate with water, which dissociates to leave the iron oxide
surface hydroxyl functionalized. These hydroxyl groups may react
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with acids or bases. Depending upon the pH of the solution, the
surface of the magnetite will be positive or negative. The isoelectric
point is observed at pH 6.8. Around this point, point of zero charge
(PZC), the surface charge density is too small and the particles are no
longer stable in water and flocculate.
The steric force depends upon the coating shell (organic or inorganic
compounds, polymer or surfactants) and it is difficult to predict and
quantify. It is quite well described for polymers and it depends,
among other parameters, upon molecular weight and density19,20.
Moreover, metal oxide or pure metal nanoparticles are very sensitive
to air, therefore it is necessary to develop efficient strategies to
improve the chemical stability of magnetic nanoparticles. Generally
core-shell structures are used to isolate the magnetic core against the
environment and to create repulsive (mainly steric) forces to balance
the magnetic and van der Waals attractive forces.
The applied coating strategies can be divided in: coatings with
organic shells, including surfactants and polymers, carboxylates,
phosphates, sulfates or coatings with inorganic compounds,
including silica, carbon or precious metals (Ag or Au).
Some of the main coating stabilizers are reported below:
Monomeric stabilizers (carboxylates, phosphates and sulfates)21.
In the case of carboxylates, the surface of metal oxide nanoparticles
can be stabilized in an aqueous dispersion by the adsorption of citric
acid22. This acid may be adsorbed on the surface of nanoparticles by
coordinating via one or two of the carboxylate functionalities,
depending upon steric necessity and the curvature surface.
Carboxylates have important effects on the growth of iron oxide
nanoparticles and their magnetic properties. Increasing concentration
of citric acid caused significant decreases in the cristallinity of the
metal oxides and changes in their surface geometry23. Similar results
have been obtained with other monomeric stabilizers, such as
gluconic acid, dimercaptosuccinic acid, oleic acid, lauric acid and
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phosphates. According to the used monomeric stabilizer,
nanoparticles could be dispersed in aqueous or organic solvents.
Surfactants and Polymers are often employed to passivate the
surface of the nanoparticles during and after the synthesis to avoid
agglomeration. In general, they can be chemically anchored or
physical adsorbed on magnetic nanoparticles to form a single or a
double layer. Surfactants, such as tetramethylammonium hydroxide
(TMAOH), sodium dodecyl sulfate (SDS), cetyltrimethylammonium
bromide (CTAB), are used to achieve stable colloids24,25. Polymers
containing functional groups, such as carboxylic acids, phosphates
and sulfates can bind to the surface of nanoparticles. The common
polymer coatings are: dextran, carboxymethylated dextran,
carboxydextran, polyvinyl alchol (PVA), polyethylene glycol (PEG),
polyoaxamines, alginate, chitosan26,27.
Inorganic materials (silica or precious metals)10,11,28. These coatings
provide stabily and help in binding various biological ligands to the
surface of nanoparticles. Silica coating, previously discussed in sol-
gel synthesis, stabilizes nanoparticles in two different ways. One is by
shielding the magnetic dipole interaction with the silica shell; on the
other hand, silica is negative charged and can enhance the Coloumb
repulsion of the magnetic nanoparticles.
Precious metals can be deposited on magnetic nanoparticles through
reactions in microemulsion, redox transmetallation or other
methods29. Gold seems to be an ideal coating owing to its low
reactivity. However it was found that the direct coating of magnetic
nanoparticles with gold is very difficult.
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2.2 Preparation of lipid vesicles
Various types of phospholipid vesicles (MLV, SUV, LUV, GUV) can be
prepared by different methods implying different mechanisms in the
liposome formation. The most common methods are:
- Hydration for multilamellar vesicles (MLV)
- Sonication for small unilamellar vesicles (SUV)
- Extrusion for large unilamellar vesicles (LUV)
- Electroformation for giant unilamellar vesicles (GUV)
Lipid vesicles are formed when thin phospholipid films are hydrated
and stacks of liquid crystalline bilayers become fluid and swell. The
hydrated lipid sheets detach during agitation and self-close to form
large, multilamellar vesicles (MLV) which prevents interaction of
water with the hydrocarbon core of the bilayer at the edges. Once
MLV have formed, SUV and LUV can be produced reducing the
vesicle sizes as reported in Figure 2.2.
Figure 2.2. Schematic of liposome preparation
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Hydration for MLV preparation consists on lipid dissolution in an
organic solvent (generally chloroform or chloroform:methanol
mixtures) to assure a homogeneous mixture of lipids. Once the lipids
are mixed in the organic solvent, the solvent is removed to yield a
lipid film. For small volumes of organic solvent (<1mL), the solvent
may be evaporated using a dry nitrogen or argon stream; for larger
volumes, the organic solvent should be removed by rotary
evaporation yielding a thin lipid. The lipid film is dried to remove
residual organic solvent under vacuum and then hydrated with an
aqueous solution. The temperature of the hydrating medium should
be above the gel-liquid crystal transition temperature (Tm) of the lipid
and should be maintained during the entire hydration period.
Swelling of the lipid film under vigorous agitation lead to the
formation of a milky suspension of heterogeneous large MLV (the size
distribution of this vesicle population is around several microns).
MLV are structures analogous to onions, with each lipid bilayer
separated by a water layer. The spacing between lipid layers is
dictated by composition and charge of the lipid.
Once these multilamellar vesicles have formed, reducing the size of
the vesicles (SUV and LUV) requires energy input in the form of sonic
energy (sonication) or mechanical energy (extrusion).
Sonication causes the disruption of MLV suspensions producing
small, unilamellar vesicles (SUV) with diameters in the range of 15-
50nm. The most common instrumentations for preparation of
sonicated vesicles are bath and probe tip sonicators. Probe tip
sonicators deliver high-energy input to the lipid suspension but
suffer from overheating of the solution causing phospholipid
degradation, the sonication tips also tend to release titanium
particles into the lipid suspension, which must be removed by
centrifugation. For these reasons, bath sonicators are the most
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widely used. Since it is nearly impossible to reproduce the conditions
of sonication, size variation between batches produced at different
times is not uncommon. Also, due to the high degree of curvature of
these membranes, SUV are unstable and will spontaneously fuse to
form larger vesicles when stored below their phase transition
temperature.
Extrusion is a technique in which a lipid suspension is forced
through a polycarbonate filter with a defined pore size to yield
particles having a diameter near the pore size of the filter used. Prior
to extrusion through the final pore size, MLV suspensions are
disrupted either by several freeze-thaw cycles or by prefiltering the
suspension through a large pore size filter. As with all procedures for
downsizing vesicle dispersions, the extrusion should be done at a
temperature above the Tm of the lipid. Extrusion through filters with
100nm pores typically yields large unilamellar vesicles (LUV) with a
mean diameter of 120-140nm. Mean particle size also depends on
lipid composition and it is quite monodisperse and reproducible from
batch to batch.
Electroformation is a useful method for the formation of cell-size
lipid membrane vesicles or GUV with diameters between 1 and 100
µm, used as model in studies of the basic properties of the cell
membrane and the functions of biomolecules. This method was first
developed by Angelova and Dimitrov and has become widely used for
preparing GUV30,31.
In the conventional electroformation method a lipid film is dried on
the conductive surface of one or both electrodes of Indium Tin Oxide
(ITO)-coated coverslips positioned parallel to each other. The reason
for using ITO as an electrode is its transparency, so that the
formation of giant vesicles could be easily observed using a
microscope. The application of a low-voltage AC electric field
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(generally a sinusoidal wave with a frequency of 10 Hz and amplitude
of 2 V) induces the formation of GUV upon swelling of a lipid
hydrated with an aqueous buffer. The disadvantage of this method is
that GUV yield and size decrease strongly when ions (salt) are present
in the aqueous solution.
In this work GUVs were prepared by using a homemade chamber (see
Figure 2.3) obtained by assembling two Indium Tin Oxide (ITO)-
coated microscope slides separated by an O-ring spacer. The
electrical connection with either side of the capacitor was obtained by
directly attaching two Cu stickers on the conducting faces.
Figure 2.3. Home-made chamber for GUVs preparation by electroformation
method.
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2.3 Small Angle Scattering (SAS)
Small angle scattering (SAS) is the collective name given to the
techniques of small angle neutron (SANS), X-Ray (SAXS) and light
(LS) scattering. In each of these techniques radiation is elastically
scattered by a sample and the resulting scattering pattern is analyzed
to provide information about the size and shape of some component
of the sample. The type of sample that can be studied by SAS, the
sample environment, the length scale and the information that can
ultimately be obtained, all depend on the nature of the radiation
employed. For example, LS cannot be used to study optically opaque
samples and SAXS cannot be employed to study large particles or
complexes samples. However, these techniques have some
similarities, for example the fact that, with minor adjustments to
account for the different types of radiation, the same basic equations
or  “laws” can be used to analyse data. In Table 2.1 I have
summarized the main features of these techniques, and we can see
that they are sensible to different aspects of the investigated
molecules, therefore they investigate different sizes of matter.
Table 2.1 Small Angle Scattering techniques
Radiation X-Rays Neutron Light (laser)
Wavelength 1-50 nm 10-150 nm 100-1000 nm
Sensible to Electron density Nuclear density  Refractive index
Technique SAXS SANS LS
Sample thick 1-2 mm 1-2 mm 1-10 mm
In any SAS experiment, a beam of collimated radiation is directed at
a sample, illuminating a small volume, V. Some of the incident
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radiation is transmitted by the sample, some is adsorbed and some is
scattered. In SAS experiments, the detector measures the intensity of
the radiation, I(Q), scattered by a collection of uniform particle.
The quantity colloquially referred to as “the scattering vector”, Q, is
the modulus of the resultant between the incident, ki, and the
scattered, ks, wavevectors, see Figure 2.4, and is given by:
€ 
Q = k f − ki =
4πn
λ
sin(θ /2)                                                                (2.1)
where Q is normally quoted in Å-1, θ/2 is the scattering angle, n is
the refractive index.
Figure 2.4. Scheme of a SAS experiment
In this section the SAS techniques used for the particles
characterization are outlined: Small Angle X-Rays Scattering (SAXS)
and Dynamic Light Scattering (DLS).
2- Methods
_____________________________________________________________
51
2.3.1 Small Angle X-Rays Scattering (SAXS)
SAXS is a small angle scattering technique where the elastic
scattering of X-rays by a sample is recorded at very low angles
(typically 0.1-10°). In this angular range, information about the
averaged particle sizes, shapes, distributions and orientation of
samples are contained. The analyzed materials can be solid or liquid
and include colloids of all types, metals, cements, oil, polymers,
proteins etc. The method is accurate, non-destructive and requires
only a minimum of sample preparation.
In a SAXS instrument a monochromatic beam of X-rays is brought to
a sample from which some of the X-rays scatter, while most simply go
through the sample without interacting with it. The scattered X-rays
form a scattering pattern detected at a detector situated behind the
sample perpendicular to the direction of the primary beam that
initially hit the sample. The scattering pattern contains the
information on the structure of the sample. The major problem that
must be overcome in SAXS instrumentation is the separation of the
weak scattered intensity from the strong main beam. The smaller the
desired angle, the more difficult this becomes. The problem is
comparable to one encountered when trying to observe a weakly
radiant object close to the sun, like the sun's corona. Likewise, in
SAXS the non-scattered beam that merely travels through the sample
must be blocked, without blocking the closely adjacent scattered
radiation. Most available X-ray sources produce divergent beams and
this compounds the problem. In principle the problem could be
overcome by focusing the beam, but this is not easy when dealing
with X-rays and was previously not done except on synchrotrons
where large bent mirrors can be used. This is why most laboratory
small angle devices rely on collimation instead.
In SAXS experiments, the measured intensity of the radiation, I(Q),
scattered by a collection of uniform particles is given by32:
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€ 
I(Q) = A ⋅ φ ⋅ P(Q) ⋅ S(Q) + Ibkg                                                          (2.2)
where A is the amplitude accounting for the instrumental factor, φ is
the particle volume fraction, P(Q) is the particles form factor, S(Q) is
the interparticle structure factor accounting for the interparticle
correlations, Ibkg is the incoherent background and Q is the scattering
vector.
The contrast term is the difference of scattering lenght density (SLD)
values between the part of the sample and the surrounding medium,
and in SAXS it arises out of the differences in electron density.
The form factor, P(Q), is a function that describes how the scattering
vector, Q, is modulated by interference effects between radiation
scattered by different parts of the same scattering body; consequently
it is very dependent on the shape of the scattering body. Fortunately
analytic expressions exist for most common shapes and expressions
for more complexes topologies can usually be deduced from these.
The interparticle structure factor, S(Q), is a function that describes
how Q is modulated by interference effects between radiation
scattered by different scattering bodies; consequently it dependent on
the degree of local order in the sample and on the sample
concentration. Generally, for diluted system, S(Q) can be discarded
and considered equal to 1.
SAXS measurements were carried out with a HECUS SWAX-camera
(Kratky) equipped with a position-sensitive detector (OED 50 M)
containing 1024 channels of width 54 µm. CuKα radiation of
wavelength 1.542 Å has been obtained using a X-ray generator
(Seifert ID-3003), operating at a maximum power of 2 kW. A 10 µm
thick nickel filter was used to remove CuKα radiation. The volume
between the sample and the detector was kept under vacuum (P < 1
mBar) during measurements to minimize scattering from air. The
liquid samples were filled into 1 mm quartz capillary and then sealed.
Measurements were done at 25°C and temperature was controlled by
a Peltier element, with an accuracy of ± 0.1 °C. All scattering curves
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were corrected for the solvent contribution. The data were slit
desmeared by a linear method33.
2.3.2 Dynamic Light Scattering (DLS)
DLS is one of the most popular methods used to determine the size of
particles. When light hits small particles, the light scatters in all
directions (Rayleigh scattering) so long as the particles are small
compared to the wavelength. If the light source is a laser, and thus is
monochromatic and coherent, then one observes a time-dependent
fluctuation in the scattering intensity. These fluctuations are due to
the fact that the small molecules in solutions are undergoing
Brownian motion and so the distance between the scatterers in the
solution is constantly changing with time. This scattered light then
undergoes either constructive or destructive interference by the
surrounding particles and within this intensity fluctuation.
There are several ways to derive dynamic information about particles'
movement in solution by Brownian motion. One such method is
dynamic light scattering (DLS), also known as quasi-elastic laser light
scattering (QELS). The dynamic information of the particles is derived
from an autocorrelation of the intensity trace recorded during the
experiment. The second order autocorrelation curve is generated from
the intensity trace as follows:
€ 
g2(q,t) = I(t)I(t + τ)
I(t) 2
                                                                (2.3)
where g2(q, τ) is the autocorrelation function at a particular wave
vector, q, and delay time, τ, and I is the intensity. At short time
delays, the correlation is high because the particles do not have a
chance to move to a great extent from the initial state that they were
in. The two signals are thus essentially unchanged when compared
after only a very short time interval. As the time delays become
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longer, the correlation starts to exponentially decay to zero, meaning
that after a long time period has elapsed, there is no correlation
between the scattered intensity of the initial and final states. This
exponential decay is related to the motion of the particles, specifically
to the diffusion coefficient. To fit the decay (i.e., the autocorrelation
function), numerical methods are used, based on calculations of
assumed distributions. If the sample is monodisperse then the decay
is simply a single exponential. The Siegert equation relates the
second order autocorrelation function with the first order
autocorrelation function g1(q; τ) as follows:
€ 
g2(q,τ ) =1+ β g1(q,t)[ ]
2
                                                                (2.4)
where the parameter β is a correction factor that depends on the
geometry and alignment of the laser beam in the light scattering
setup.
Once the autocorrelation data have been generated, different
mathematical approaches can be employed to determine size and
polydispersity of particles from it. Analysis of the scattering is
facilitated when particles do not interact through collisions or
electrostatic forces between ions. Particle-particle collisions can be
suppressed by dilution, and charge effects are reduced by the use of
salts to collapse the electrical double layer.
The simplest approach is to treat the first order autocorrelation
function as a single exponential decay. This is appropriate for a
monodisperse population.
€ 
g1(q,τ ) = exp(−Γτ)                                                                      (2.5)
where Γ is the decay rate. The translational diffusion coefficient Dt
may be derived at a single angle or at a range of angles depending on
the scattering wave vector q (defined in equation 2.1).
€ 
Γ = q2Dt                                                                                   (2.6)
The diffusion coefficient Dt provide access to the hydrodynamic
correlation lengths RH for isotropic particles through the Stokes-
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Einstein relationship:
€ 
Dt =
kBT
6πηsRH
                                                                    (2.7)
where ηS is the solvent viscosity and kB the Boltzmann constant.
It is important to note that the size determined by dynamic light
scattering is the size of a sphere that moves in the same manner as
the scatterer. So, for example, if the scatterer is a random coil
polymer, the determined size is not the same as the radius of gyration
determined by static light scattering. It is also useful to point out that
the obtained size will include any other molecules or solvent
molecules that move with the particle. In most cases, samples are
polydisperse. Thus, the autocorrelation function is a sum of the
exponential decays corresponding to each of the species in the
population.
One of the most common methods to fit DLS autocorrelation
functions is the Cumulant method, from which in addition to the sum
of the exponentials above, more information can be derived about the
polidispersity of the system as follows:
€ 
g1(q,τ ) = exp(−Γτ)(1+ µ22! τ
2 −
µ3
3! τ
3 + ...)                                     (2.8)
where 
€ 
µ2
2! τ
2 is the second  order polydispersity index.
An alternative method for analyzing the autocorrelation function can
be achieved through an inverse Laplace transform known as
CONTIN34.The CONTIN analysis is ideal for polydisperse and
multimodal systems.
DLS experiments were carried out on a Brookhaven Instrument
apparatus, New York, USA (BI 9000 AT correlator card and BI 200
SM goniometer). The signal is detected by an EMI 9863B/350
photomultiplier. The light source was the doubled frequency of a
Coherent Innova diode pumped Nd-YAG laser, (λ=532 nm, 20 mW), or
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alternatively a JDS Uniphase He-Ne (λ=633 nm, 5 mW). The laser
long term power stability was ± 0.5%. Self-beating detection was
recorded using decahydronaphthalene (thermostated by a water
circulating system) as index matching liquid. A temperature probe
was inserted in the sample while simultaneously recording
autocorrelation functions. Measurements have been performed at
25°C on 0.5 ml samples previously transferred into cylindrical Hellma
scattering cells. For each sample at least three separate
measurements were performed at the scattering angle θ = 90°
corresponding to the scattering vector q. Data analysis has been
performed according to standard procedures, and interpreted
through a cumulant expansion of the field autocorrelation function,
arrested to the second order. Moreover, in order to obtain a
distribution w(Γ) of decay rates, a constrained regularization method,
CONTIN, developed by Provencher, was used to invert the
experimental data.
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2.4 Microscopy
Microscopy is the technical field of using microscopes to view
samples or objects that cannot be seen with the unaided eye (objects
that are not within the resolution range of the normal eye). There are
three well-known branches of microscopy: optical, electron, and
scanning probe microscopy. Optical and electron microscopy involve
the diffraction, reflection, or refraction of electromagnetic
radiation/electron beams interacting with the subject of study, and
the subsequent collection of this scattered radiation in order to build
up an image. This process may be carried out by wide-field
irradiation of the sample (for example standard light microscopy and
transmission electron microscopy) or by scanning of a fine beam over
the sample (for example confocal laser scanning microscopy and
scanning electron microscopy).
In the following paragraphs the principles of Confocal Laser Scanning
Microscopy (CLSM) are reported, because this technique was widely
used for the experiments performed in this work. Moreover some
information about Transmission Electron Microscopy (TEM) are
reported.
2.4.1 Confocal Laser Scanning Microscopy
(CLSM)
Laser scanning confocal microscopy has become an invaluable tool
for a wide range of investigations in the biological and medical
sciences for imaging thin optical sections in living and fixed
specimens ranging in thickness up to 100 micrometers. CLSM is a
technique for obtaining high-resolution optical images with depth
selectivity. The key feature of confocal microscopy is its ability to
2- Methods
____________________________________________________________________
58
acquire in-focus images from selected depths, a process known as
optical sectioning. Images are acquired point-by-point and
reconstructed with a computer, allowing three-dimensional
reconstructions of topologically-complex objects. The principle of
CLSM was developed by Marvin Minsky in 1957, but it took another
thirty years and the development of lasers for CLSM to become a
standard technique toward the end of the 1980s. In 1978, Thomas
and Christoph Cremer designed a laser scanning process, which
scans the three dimensional surface of an object point-by-point by
means of a focused laser beam, and creates the over-all picture by
electronic means similar to those used in scanning electron
microscopes. This CLSM design combined the laser scanning method
with the 3D detection of biological objects labeled with fluorescent
markers for the first time.
In a conventional light microscope, object-to-image transformation
takes place simultaneously and parallel for all object points. By
contrast, the specimen in a CLSM is irradiated in a point-wise
fashion, i.e. serially, and the physical interaction between the laser
light and the specimen detail irradiated (e.g. fluorescence) is
measured point by point. To obtain information about the entire
specimen, it is necessary to guide the laser beam across the
specimen, or to move the specimen relative to the laser beam, a
process known as scanning. To obtain images of microscopic
resolution from a CLSM, a computer and dedicated software are
indispensable.
The principle of CLSM is diagrammatically presented in Figure 2.5.
Coherent light emitted by the laser system (excitation source) passes
through a pinhole aperture that is situated in a conjugate plane
(confocal) with a scanning point on the specimen and a second
pinhole aperture positioned in front of the detector (a photomultiplier
tube). As the laser is reflected by a dichromatic mirror and scanned
across the specimen in a defined focal plane, secondary fluorescence
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emitted from points on the specimen (in the same focal plane) pass
back through the dichromatic mirror and are focused as a confocal
point at the detector pinhole aperture.
Only a small fraction of the out-of-focus fluorescence emission is
delivered through the pinhole aperture, most of this extraneous light
is not detected by the photomultiplier and does not contribute to the
resulting image. Refocusing the objective in a confocal microscope
shifts the excitation and emission points on a specimen to a new
plane that becomes confocal with the pinhole apertures of the light
source and detector.
Figure 2.5. Schematic diagram of the optical pathway and principal components of
CLSM.
With a CLSM it is possible to exclusively image a thin optical slice out
of a thick specimen (typically, up to 100 µm), a method known as
optical sectioning. Under suitable conditions, the thickness (Z
dimension) of such a slice may be less than 500 nm.
A CLSM can therefore be used to advantage especially where thick
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specimens (such as biological cells in tissue) have to be examined by
fluorescence. The possibility of optical sectioning eliminates the
drawbacks attached to the observation of such specimens by
conventional fluorescence microscopy.
In addition to the possibility to observe a single plane (or slice) of a
thick specimen in good contrast, optical sectioning allows a great
number of slices to be cut and recorded at different planes of the
specimen, with the specimen being moved along the optical axis (Z)
by controlled increments.
The result is a 3D data set, which provides information about the
spatial structure of the object. The quality and accuracy of this
information depend on the thickness of the slice and on the spacing
between successive slices.
Another field of growing importance is the investigation of living
specimens that show dynamic changes even in the range of
microseconds. Here, the acquisition of time-resolved confocal image
series (known as time series) provides a possibility of visualizing and
quantifying the changes.
In this work confocal images of fluorescent GUVs were acquired using
a DMIRE2 Confocal Microscope (Leica TCS SP2) with argon ion lasers
(λ=488 nm and 514 nm, 30mW at 30% of maximum power) and a
water immersion objective 63x/1.2W (Zeiss). The samples were
placed in home-made cells, where the bottom plate was a microscopy
coverglass (LAB-TEC, 8 Well) and the cell wall was a cylinder of glass
(diameter 8 mm, height 1.5 cm). All leakage experiments were
quantitatively analyzed by measuring the change in fluorescence
intensity of the probe (Alexa 488-maleimide) in the aqueous pool
inside the GUVs during the exposure to an AC-magnetic field.
2.4.2 Transmission Electron Microscopy (TEM)
The transmission electron microscope (TEM) operates on the same
basic principles as the light microscope but uses electrons instead of
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light. What you can see with a light microscope is limited by the
wavelength of light. TEM use electrons as "light source" and their
much lower wavelength makes it possible to get a resolution a
thousand times better than with a light microscope. It is possible to
see objects to the order of a few Angstrom (10-10 m). For example, one
can study small details in the cell or different materials down to near
atomic levels, making TEM a valuable tool in both medical, biological
and materials research. A "light source" at the top of the microscope
emits the electrons that travel through vacuum in the column of the
microscope. Instead of glass lenses focusing the light in the light
microscope, TEM uses electromagnetic lenses to focus the electrons
into a very thin beam. The electron beam then travels through the
specimen you want to study. Depending on the density of the
material present, some of the electrons are scattered and disappear
from the beam. At the bottom of the microscope the unscattered
electrons hit a fluorescent screen, which gives rise to a "shadow
image" of the specimen with its different parts displayed in varied
darkness according to their density. The image can be studied
directly by the operator or photographed with a camera.
TEM investigations have been carried out using a Philips CM 12
operating at acceleration voltages up to 120 kV, equipped with an
Olympus MegaViewG2 side-mounted CCD camera. Magnetic
nanoparticle samples were prepared by placing a drop of the
suspension on a carbon-coated copper grid with a carbon membrane
film and removing the excess solvent with a filter paper.
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2.5 Fluorescence Spectroscopy
Fluorescence is a spectrochemical method of analysis where the
molecules of the analyte  are excited by irradiation at a certain
wavelength and emit radiation of a different wavelength. The emission
spectrum provides information for both qualitative and quantitative
analysis.
In this work, fluorescence spectroscopy was used to investigate the
release behaviour of the fluorescent molecule Carboxyfluorescein (CF)
embedded in magnetoliposomes. Steady-state fluorescence was
measured with a LS50B spectrofluorimeter (Perkin Elmer, Italy). The
emission fluorescence spectra of CF were recorded between 500 and
610 nm in the corrected spectrum mode with excitation wavelength
set at 492 nm and 2.5 nm slit. At least 5 scans were averaged for
each spectrum. Magnetoliposomes and control solutions (diluted
1:150 with the isotonic buffer) were measured, before and after LF-
AMF exposure, at regular time intervals. The release behaviour was
checked in time-drive modality by measuring the fluorescence
intensity every 10 min during 15 hours. Fluorescence experiments
were also performed on magnetoliposomes and control liposomes
kept at the highest temperature reached during the treatment, for the
same exposure time. All samples were diluted to the measurement
concentration with a solution of Triton X-100 to achieve complete
release of CF through vesicles disruption. The release percentage was
calculated from the fluorescence intensity as:
€ 
%Re lease = IML (t) − IML (0)IMAX − IML (0)
×100                                                     (2.9)
where IML(t) is the measured fluorescence intensity, IML(0) is the
fluorescence intensity of the untreated sample, and IMAX is the
maximum fluorescence emission with Triton X-100 addition.
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2.6 Differential Scanning Calorimetry
(DSC)
Differential scanning calorimetry (DSC) is a thermo-analytical
technique in which the difference in the amount of heat required to
increase the temperature of a sample and reference is measured as a
function of temperature. Both the sample and reference are
maintained at nearly the same temperature throughout the
experiment. The reference sample should have a well-defined heat
capacity over the range of temperatures to be scanned. DSC has been
of primary importance in studies of lipid phase transitions in model
and biological membranes. The basic principle underlying this
technique is that, when the sample undergoes a physical
transformation such as phase transitions, more or less heat will need
to flow to it than the reference to maintain both at the same
temperature. Whether less or more heat must flow to the sample
depends on whether the process is exothermic or endothermic. For
example, as a solid sample melts to a liquid it will require more heat
flowing to the sample to increase its temperature at the same rate as
the reference. This is due to the absorption of heat by the sample as
it undergoes the endothermic phase transition from solid to liquid.
Likewise, as the sample undergoes exothermic processes (such as
crystallization) less heat is required to raise the sample temperature.
By observing the difference in heat flow between the sample and
reference, differential scanning calorimeters are able to measure the
amount of heat absorbed or released during such transitions. DSC
curves can be used to calculate enthalpies of transitions by
integrating the peak corresponding to a given transition. It can be
shown that the enthalpy of transition can be expressed using the
following equation:
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€ 
ΔH = KA                                                                            (2.10)
where ΔH is the enthalpy of transition, K is the calorimetric constant,
and A is the area under the curve. The calorimetric constant will vary
from instrument to instrument, and can be determined by analyzing
a well-characterized sample with known enthalpies of transition.
The transition temperature, associated to gel/fluid transition of the
lipid bilayer of liposomes, was determined by differential scanning
calorimetry measurements performed using a DSC Q2000 from TA
Instruments. Heating scans were performed on both liposomes and
magnetoliposomes solutions (25 mg/L of lipid) in hermetically closed
aluminum pans, in the temperature range from –40 to 25°C at
1°C/min, in order to detect possible differences associated to different
lipid packing and bilayer viscosity due to the presence of
nanoparticles. Moreover the liposomes and magnetoliposomes
solutions, previously exposed to LF-AMF, have been analyzed every
two hours with the same heating scan in order to clarify the effect of
the nanoparticles on the lipid bilayers upon the application of a
magnetic field.
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2.7 Attenuated Total Reflection Infrared
Spectroscopy (ATR-FTIR)
An ATR-FTIR apparatus operates by measuring the changes that
occur in a totally internally reflected infrared beam when the beam
comes into contact with a sample. An infrared beam is directed onto
an optically dense crystal with a high refractive index at a certain
angle. This internal reflectance creates an evanescent wave that
extends beyond the surface of the crystal into the sample held in
contact with the crystal. It can be easier to think of this evanescent
wave as bubble of infrared that sits on the surface of the crystal. This
evanescent wave protrudes only a few microns beyond the crystal
surface and into the sample. Consequently, there must be good
contact between the sample and the crystal surface. In regions of the
infrared spectrum where the sample absorbs energy, the evanescent
wave will be attenuated or altered. The attenuated energy from each
evanescent wave is passed back to the IR beam, which then exits the
opposite end of the crystal and is passed to the detector in the IR
spectrometer. The system then generates an infrared spectrum.
Generally diamond is by far the best ATR crystal material because of
its robustness and durability.
In this work IR spectra were collected with a Nexus 870
spectrophotometer (Thermo Nicolet, Paris, France) equipped with a
liquid nitrogen-cooled Mercury Cadmium Telluride detector and a
single reflection diamond crystal ATR unit (Golden Gate, Specac, UK).
All spectra were performed at room temperature with 4 cm_1
resolution and averaging 256 scans. The reference spectra, in this
case water, were subtracted from the absorbance spectra of the
investigated samples.
2- Methods
____________________________________________________________________
66
2.8 Magnetic field generator
A sinusoidal adjustable magnetic field was generated in the gap of a
broken ferrite ring carrying a solenoid through which an alternating
electric current (AC) from a tone generator was led (Figure 2.6).
Samples to be treated with LF-AMF were placed in the middle of the
gap within 1 cm cylindrical quartz cells. Due to the design of the
experimental apparatus, the magnetic field inside the cell is not
isotropic. In fact magnetic field values at different positions of the
broken toroidal magnet used to apply the LF-AMF were measured by
means of a GM-07 Gaussmeter (HIRST Magnetic Instruments Ltd,
UK). Since the measured magnetic fields are different, the sample
undergoes magnetic field gradients that cannot be avoided.
Figure 2.6.  Picture of the broken toroidal magnet used to apply the LF-
AMF. Magnetic field values at different positions of the broken toroidal
magnet.
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2.9 Magnetic measurements: SQUID
Magnetic properties of the investigated samples where determined by
SQUID (Superconducting Quantum Interference Device), which is a
very sensitive magnetometer used to measure extremely weak
magnetic fields. SQUID is a simple and rapid way to estimate the
blocking temperature and the magnetism of a sample.
The blocking temperature is determined by a zero field cooled/field
cooled procedure: the sample is cooled from room temperature in a
zero magnetic field (ZFC) and in a magnetic field (FC). Then a small
magnetic field is applied (about 100 Oe) and the magnetization is
recorded on warming. As temperature increases, the thermal energy
disturbs the system and more moments acquire the energy to be
aligned with the external field direction. The number of unblocked,
aligned moments reaches a maximum at the blocking temperature.
Above the blocking temperature the thermal energy is strong enough
to randomize the magnetic moments leading to a decrease in
magnetization. The blocking temperature is the temperature
corresponding to the contact point between the ZFC and FC curves.
The magnetic properties of a material can be determined from its
hysteresis loop. A hysteresis loop shows the relationship between the
induced magnetic flux density (B) and the magnetizing force (H). An
example hysteresis loop is shown in Figure 2.7.
The loop is generated by measuring the magnetic flux of a material
while the magnetizing force is changed. As the line demonstrates, the
greater the amount of current applied (H+), the stronger the magnetic
field in the component (B+). At point a almost all of the magnetic
domains are aligned and an additional increase in the magnetizing
force will produce very little increase in magnetic flux. The material
has reached the point of magnetic saturation. When H is reduced to
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zero, the curve will move from point a to point b. At this point, it can
be seen that some magnetic flux remains in the material even though
the magnetizing force is zero. This is referred to as the point of
retentivity on the graph and indicates the remanence or level of
residual magnetism in the material. As the magnetizing force is
reversed, the curve moves to point c, where the flux has been
reduced to zero. This is called the point of coercivity on the curve. The
force required to remove the residual magnetism from the material is
called the coercive force or coercivity of the material.
Figure 2.7. Hysteresis loop of a magnetic material
As the magnetizing force is increased in the negative direction, the
material will again become magnetically saturated but in the opposite
direction (point d). Reducing H to zero brings the curve to point e. It
will have a level of residual magnetism equal to that achieved in the
other direction. Increasing H back in the positive direction will return
B to zero. Notice that the curve did not return to the origin of the
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graph because some force is required to remove the residual
magnetism. The curve will take a different path from point f back to
the saturation point where it completes the loop.
AC susceptibility measurements give information about
magnetization dynamics in function of temperature and at different
magnetic field oscillating frequencies. In AC magnetic measurements,
a small AC drive magnetic field is superimposed on the DC field,
causing a time-dependent moment in the sample. The field of the
time-dependent moment induces a current in the pickup coils,
allowing measurement without sample motion. The detection
circuitry is configured to detect only in a narrow frequency band,
normally at the fundamental frequency (that of the AC drive field).
The AC magnetic susceptibility measurement yields two quantities:
the magnitude of the susceptibility, χ, and the phase shift, ϕ (relative
to the drive signal). Alternately, one can think of the susceptibility as
having an in-phase, or real, component χ', and an out-of-phase, or
imaginary, component χ". The two representations are related by:
€ 
χ '= χ cosϕ                                                                        (2.11)
€ 
χ"= χ sinϕ                                                                        (2.12)
The imaginary component, χ", indicates dissipative processes in the
sample.
In conductive samples, the dissipation is due to eddy currents.
Relaxation and irreversibility in spin-glasses give rise to a nonzero χ".
In ferromagnets, a nonzero imaginary susceptibility can indicate
irreversible domain wall movement or absorption due to a permanent
moment. Also, both χ' and χ" are very sensitive to thermodynamic
phase changes, and are often used to measure transition
temperatures.
Magnetic measurements on nanoparticles and magnetoliposomes
were performed with a MPMS SQUID magnetometer (Quantum
Design, San Diego, USA) mounting a liquid helium cryostat able to
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cool the sample down to 1.8 K and a superconducting coil magnet
capable of reaching 6 T static magnetic field. All static magnetization
measurements were carried out on water dispersions of the samples;
magnetization curves were recorded at 2.5 K and 300 K. The data
were corrected for the diamagnetic contribution of the solvent and of
the sample holder, which were separately measured.
AC susceptibility measurements were carried out in the 1-1000 Hz
frequency range and performed both on pressed pellets of solid
Cobalt ferrite NPs and on water solution of magnetoliposomes.
2- Methods
_____________________________________________________________
71
2.10 Inductively coupled plasma–atomic
emission spectrometry (ICP-AES)
A VARIAN 720 OES inductively coupled plasma optical emission
spectrometer (ICP-AES) was used for the determination of iron and
Cobalt content (ppm) inside magnetoliposomes. The samples were
diluted from 0.1 ml to 5.0 ml in 0.1% nitric acid. Calibration curves
of standard solutions of iron and Cobalt have been used. The ICP-
AES was programmed to detect Co (238.892; 228.615; 230.786 nm)
and Fe (238.204; 259.940; 234.350 nm) and to give the average value
of the obtained results for each metal. An internal standard of Ge 5
ppm (209.426 nm) has been used to correct for matrix effects.
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3.1 Uncoated Cobalt Ferrite nanoparticles
Materials: Iron(III) chloride hexahydrate (97%), Cobalt(II) nitrate
hexahydrate (98%), Sodium hydroxide (minimum 98%),
tetramethylammonium hydroxide 25%wt solution in water (TMAOH),
Sodium chloride (minimum 99.5%) from Sigma-Aldrich, and
concentrated nitric acid (90%) from Fluka.
Cobalt Ferrite nanoparticles were prepared by the co-precipitation
method, introducing minor modifications to the Massart’s method1,2.
Briefly, aqueous solutions of 1 M FeCl3 (64 ml) and Co(NO3)2 (32 ml)
were added to concentrated nitric acid (2 ml). The mixture was heated
to the boiling point and then, as fast as possible, mixed under
vigorous agitation with 1 M NaOH solution (400 ml) warmed up till
boiling. The boiling temperature and the stirring were maintained for
90 minutes. The particles obtained were separated by magnetic
decantation, washed with water and added to 2 M HNO3 (40 ml). The
precipitate was again separated by magnetic decantation, dispersed
in a boiling solution obtained by dissolving 0.5 M FeCl3 (56 ml) and
0.5 M Co(NO3)2 (28 ml) and kept under vigorous agitation for 30
minutes. The precipitate obtained after this treatment was isolated
and washed with water3,4 .
To prepare larger nanoparticles the same synthetic procedure was
used, but the Co(II), Fe(III), NaOH mixture was kept to the boiling
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temperature during 120 minutes. For negatively charged CoFe2O4
nanoparticles, the precipitate was dispersed in 0.25 M TMAOH
solution. For positively charged CoFe2O4 nanoparticles, the
precipitate was washed with HNO3 1 M (30 ml) and then dispersed in
water. The concentration of the nanoparticles was checked by
inductively coupled plasma atomic mission spectrometer (ICP-AES)
and eventually adjusted by dilution or increased by means of an
ultrafiltration cell (Amicon, Millipore corporation).
Characterization
Uncoated cobalt–ferrite nanoparticle dispersions were
characterized by SAXS and DLS.
SAXS spectra of these solutions, corrected for the solvent, are
reported in figure 3.1a and 3.1b.
The scattering intensity due to small CoFe2O4 nanoparticles
(negatively and positively charged) was modelled according to the
formalism introduced by Bartlett and Ottewill for polydisperse
spherical particles5. In this approach, the particles are described as
spherical objects with a Schulz distribution of radii6. In particular,
the model accounts for a polydisperse population of spheres with
uniform scattering length density. No structure factors were included
in this model: in fact, due to the low concentration of particles in the
dispersions, the interparticle interference effects can be neglected.
The model-fitting analysis of Schulz sphere is:
€ 
I(q) = ( 4π3 )
2N0Δρ2 f (R)R6
0
∞
∫ F 2(qR)dR                                       (3.1)
where N0 is the total number of particles per unit volume, Δρ is the
difference in scattered lenght density, F(qR) is the scattering
amplitude for a sphere, and f(R) is the Schulz distribution of the
radii.
€ 
f (R) = (z +1)z+1xz exp[−(z +1)x]RavgΓ(z +1)
                                              (3.2)
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where Ravg is the mean radius, z is the variance of distribution
related to polidispersity and Γ is the gamma function.
The best fittings of small magnetic NPs are reported in figure 3.1a
as solid lines. The estimated average radius <R> and the
polidispersity are reported in Table 3.1. The system is affected by a
considerable polidispersity, consistently with what observed for
similar magnetic nanoparticles. In Figure 3.1b SAXS spectrum
from larger CoFe2O4 nanoparticles is reported; the solid curve
represents the best fitting results.
For large CoFe2O4 NPs it was not possible to fit the curve as a
single population of particles, so a bimodal function has been used
and each population was modeled as polidisperse spheres of radius
R with a Schulz distribution of the radii 6 (Table 3.1). Spheres of
about 23 nm in radius are the most represented population, while
an averaged radius of 8 nm characterizes the second one.
The same samples have been investigated by DLS (Figure 3.2) and
the autocorrelation functions are well fitted with Cumulant
analysis. The obtained hydrodynamic radii, RH, and polydispersity
values are reported in Table 3.1.
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Figure 3.1. SAXS spectra (a) of small negative and positive cobalt-ferrite
nanoparticles; (b) SAXS spectra of large negative cobalt-ferrite nanoparticles.
Table 3.1. Structural parameters of CoFe2O4 nanoparticles by SAXS and
DLS
Small CoFe2O4 (-) Small CoFe2O4
(+)
Large CoFe2O4 (-)
SAXS fitting
A*φ 0.0125 0.0123 0.0105
0.0013
<R> (nm) 5.7 5.9 23.4
8.3
Polydispersity 0.44 0.42 0.21
0.20
Cumulant
analysis
RH (nm) 15.9 17.9 27.6
Polydispersity 0.20 0.21 0.19
CONTIN
<RH> 9.8 12.2 20.9
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The RH values of the nanoparticles are larger than the mean radii
estimated by SAXS analysis: in fact, the objects diffusing in the
aqueous solution are composed by the oxide cores together with their
hydration layers, which do not contribute to the scattering intensities
in SAXS experiments.
Figure 3.2. (a) Size distributions of small negative and positive cobalt-ferrite
nanoparticles;  (b) Size distribution of large negative cobalt-ferrite
nanoparticles.
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Negative uncoated Cobalt-ferrite nanoparticles were also investigated
by TEM, confirming the results obtained by SAXS experiments.
These nanoparticles were also magnetically characterized by SQUID
and AC measurements. TEM pictures and SQUID data of negative
uncoated Cobalt-ferrite nanoparticles were reported in the next
paragraph because the obtained results were compared with the ones
obtained for citrate-coated Cobalt-ferrite nanoparticles.
3.2 Citrate-coated Cobalt Ferrite
nanoparticles
Materials: Tri-Sodium citrate dihydrate (>99%), citric acid
monohydrate (>99.5%), sodium hydroxide (99.5%) were purchased
from Sigma-Aldrich. HEPES [4-(2-hydroxyethyl) piperazine-1-ethane-
sulfonic acid] (ultra >>99.5%), concentrated nitric acid (90%) were
purchased from Fluka. Uncoated Cobalt-ferrite nanoparticles
dispersed in TMAOH.
Citrate-coated Cobalt ferrite nanoparticles were prepared starting
from uncoated particles by adsorption of citric acid on their surface
through the coordination of the carboxylate functionalities7.
Negatively charged Cobalt ferrite nanoparticles (10 ml, 1% wt) in
TMAOH were added to a 100 mM citric acid solution (30 ml) and
slightly stirred for 1 h at room temperature (the resulting pH is
around 5). After recollecting the precipitate with the magnet,
nanoparticles were dispersed in 20 mM trisodium citrate (30 ml)
and kept under stirring for 45 min. The obtained particles were
separated by magnetic decantation and washed several times with
water and acetone in order to remove any excess of citric acid. The
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citrate coated nanoparticles were gently dried under a nitrogen gas
flux, dispersed in the buffer solution (10 mM HEPES, 107 mM
NaCl, 5.3 mM NaOH, pH 7.4) and kept under slight stirring for 24
h. Finally the dispersion was centrifuged at 1000 g for 2 min and
the supernatant was dialyzed against water for 24 h through a
cellulose dialysis bag (avg. flat width 23 mm, MWCO 12400,
99.99% retention) in order to remove non-adsorbed citrate species.
However a residual ionic strength is always present because of
solvated anions in equilibrium with the adsorbed ones. The
adsorption of citrate onto metal oxide surfaces has been verified by
attenuated total reflectance Fourier-transform infrared (ATR-FTIR)
spectroscopy8.
Iron and Cobalt contents in uncoated and coated nanoparticles was
checked by inductively coupled plasma atomic emission
spectrometer (ICP-AES) and eventually decreased by dilution or
concentrated by means of ultrafiltration (Amicon, Millipore
corporation).
Characterization
SAXS spectrum of citrate-coated Cobalt ferrite nanoparticles is
reported in figure 3.3 and it has been investigated through the
model fitting of spheres with a Shulz distribution of the radii.
The fitting results are reported in Table 3.2, where also the main
features of negative uncoated nanoparticles were reported for
comparison. The obtained results indicate that the radius of
citrate-coated nanoparticles is very similar to the radius previously
obtained for negative uncoated nanoparticles (the precursor). This
is due to the fact that the electronic density in Cobalt ferrite
nanoparticles largely overrules that of the citrate shell, so that
SAXS signal accounts only for the magnetic cores. SAXS fitting
shows that uncoated nanoparticles seem to be larger than coated
nanoparticles. This is reasonably due to the presence of aggregates
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formed by uncoated magnetic NPs.
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Figure 3.3. SAXS spectrum of citrate coated () Cobalt ferrite nanoparticles.
Nanoparticles dispersed in water were also characterised by DLS.
To avoid multiple scattering, samples were first diluted 100 times
with water. The DLS autocorrelation functions of citrate-coated
Cobalt ferrite nanoparticles dispersions are well fitted with
Cumulant analysis and their size distribution (obtained from a
CONTIN analysis) is compared with the small negative uncoated
ones, as shown in Figure 3.4. The obtained hydrodynamic radii,
RH, and polydispersity values are reported in Table 3.2. Citrate-
coated nanoparticles show a larger hydrodynamic radius with
respect to the uncoated ones that confirms the presence of the
citrate shell.
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Figure 3.4. Size distributions of coated and uncoated Cobalt ferrite
nanoparticles in water obtained from DLS analysis.
Table 3.2. Structural parameters of CoFe2O4 nanoparticles in water
dispersions by SAXS and DLS analysis.
Citrate coated CoFe2O4 Uncoated CoFe2O4
SAXS Fitting
<R> [nm] 4.9 5.6
Polydispersity 0.60 0.49
Cumulant analysis
RH[nm] 21.3 15.9
Polydispersity 0.15 0.20
CONTIN
<RH> [nm] 13.9 9.8
TEM images of citrate-coated Cobalt ferrite nanoparticles and
negative uncoated ones were reported in figure 3.5. TEM pictures
show that both coated and uncoated nanoparticles are quite
polydisperse and their shape is nearly spherical, in agreement with
SAXS results. In figure 3.6 the size distribution obtained from TEM
images analysis of both NP samples is reported. A comparison of
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the histograms shows that the radii of coated nanoparticles range
from 2 to 8 nm according to a lognormal distribution centered at
3.4 nm, while uncoated nanoparticles present a population ranging
between 2 and 6 nm of radius and some larger particles and
aggregates, ranging from 8 to 12 nm of radius. It is important to
stress that the citrate coating cannot be detected in TEM
micrographs, because of its poor electronic density.
Figure 3.5. TEM images of (a) negative uncoated and (b) citrate coated
Cobalt ferrite nanoparticles.
ATR-FTIR spectroscopy has been used to investigate the adsorption
of citrate on Cobalt ferrite nanoparticles surfaces9.
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Figure 3.6. Size distribution of uncoated and citrate coated nanoparticles
obtained from the analysis of TEM micrographs.
Figure 3.7 shows FTIR spectra of (a) citrate coated nanoparticles
solution (1.6% wt) at pH 7.4, (b) pure trisodium citrate solution (20
mM) and (c) citric acid solution (20 mM).
Figure 3.7. ATR-FTIR spectra of (a) citrate coated CoFe2O4 nanoparticles at
pH=7.4, (b) 20 mM tri-sodium citrate solution, (c) 20 mM citric acid
solution.
3- Drug carriers
____________________________________________________________________
86
In Table 3.3 FTIR absorption frequencies are reported together with
the corresponding assignments for all samples. The band at 1722
cm-1 for citric acid, corresponding to the C=O vibration, is not
present in the spectra of tri-sodium citrate and citrate coated
nanoparticle. This feature highlights that citric acid binds the
Cobalt ferrite surface of nanoparticles by adsorption of citrate
anions. The 1570 cm-1 and 1390 cm-1 peaks in pure citrate are
assignable to the asymmetric and symmetric C-O stretching,
respectively. Upon binding of citrate to the Cobalt ferrite surface,
the asymmetric C-O stretching band splits in two peaks at 1640
and 1570 cm-1. The 1640 cm-1 peak is the asymmetric C-O
stretching of Fe-citrate complexes, in equilibrium with free citrate
anions, whose peak remains at 1570 cm-1.
Table 3.3. FTIR vibrational assignments for citric acid, tri-sodium citrate
and adsorbed citrate on Cobalt ferrite nanoparticles
Vibrational
modes
Frequency (cm-1)
Citric acid
Frequency (cm-1)
Tri-sodium citrate
Frequency (cm-1)
Adsorbed citrate on
nanoparticles
νs (C=O) 1722  
νas (C-O) 1581 1570 1640
νs (C-O) 1397 1390 1390
δ (O=C-O)  1278-1257 1276-1185
ν (C-OH) 1220  1067
Magnetic characterization of citrate coated and uncoated
nanoparticles were performed by SQUID and AC measurements.
Low temperature hysteresis loops were measured on water
dispersions of both CoFe2O4 nanoparticles at the same concentration
(16.5 mg/ml). At low temperature, ice creates a glassy matrix that
traps the nanoparticles, thus preventing their orientation due to
torque effects induced by the applied magnetic field. As can be seen
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from Figure 3.8a, the magnetic behaviour of the two types of particles
is very similar, confirming that the citrate layer does not affect
surface anisotropy of the particles, and the capping process does not
introduce significant size alterations. The coercive field value of 9000
Oe is in line with the particle size found by SAXS and TEM
measurements.
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Figure 3.8. Magnetization curves of citrate-coated and uncoated cobalt
ferrite nanoparticles measured at 2.5 K (a) and 300 K (b).
a)
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Room temperature magnetization curves were acquired for the same
nanoparticle dispersions (Figure 3.8b). In this case, particles are free
to rotate in water; as a consequence, the low field response of the
sample is due to particle alignment with the external magnetic field,
rather than to spin orientation. By comparing the magnetization
curves of the two nanoparticle samples, it is clear that citrate coated
particles show a stronger magnetic response at low applied field than
uncoated ones. This result is a strong indication that aggregation is
likely to occur in uncoated dispersions: in fact, if a particle aggregate
dispersed in a solvent is immersed in a magnetic field, it will align
with the field. However, single particles in the aggregate still possess
a random magnetic moment distribution (Figure 3.9a), that will align,
either by mechanical rotation or spin flip across the energy barrier,
with higher magnetic field values.
Figure 3.9. Schematic picture of the behaviour of a) aggregated and b) well
dispersed magnetic particles in a fluid medium. Grey lines mimic the
magnetization value as a function of the applied field.
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In the case of well dispersed single grain particles (as in the case of
citrate coated nanoparticles) instead, a weak applied field is enough
to align all particles (Figure 3.9b). The result points out that, as
expected, the citrate coating reduces particle aggregation in solution.
AC measurements carried out on powder samples of both uncoated
and coated particles confirm that the magnetic behaviour of the
magnetic cores is very similar. Both samples show a bimodal
distribution of magnetic relaxation times (the faster under room
temperature and the slower above 300 K on the investigated
experimental time scale), coherently with the size distribution
observed in TEM analysis.
AC results of negative uncoated and citrate-coated Cobalt ferrite
NPs are reported in Figure 3.10 (a,b).
a)
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Figure 3.10. AC measurements on powder samples of (a) uncoated and (b)
citrate-coated Cobalt ferrite nanoparticles
b)
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3.3 Oleic acid-coated Cobalt Ferrite
nanoparticles
Materials: oleic acid (95%), tetramethyl ammonium hydroxide
(TMAOH; 25% wt% water solution) and cyclohexane (99.9%) were
purchased from Sigma-Aldrich. Acetone (99.5%) was purchased from
Fluka. Uncoated positively charged Cobalt-ferrite nanoparticles in
water.
Uncoated positively charged Cobalt-ferrite nanoparticles obtained by
Massart method were dispersed in water (45 ml) and poured in a
separatory funnel.  A 10% wt solution of oleic acid in cyclohexane (15
ml) was used as extraction medium for magnetic nanoparticles and
added to the water dispersion in the funnel. A 25% wt solution of
TMAOH (20 ml) was added dropwise to the mixture and vigorously
agitated in order to promote the transfer of Cobalt ferrite
nanoparticles in the cyclohexane phase where the adsorption of oleic
acid on their surface took place through the coordination of the
carboxylate functionalities. This procedure was repeated ten times in
order to extract all the nanoparticles from the aqueous to the
cyclohexane phase. The solvent of the collected organic solution was
removed by evaporation in order to take off any trace of water and
then the dry nanoparticles were washed twice with acetone (30 ml).
After recollecting the precipitate with the magnet, the Cobalt ferrite
nanoparticles covered with oleic acid were dispersed in cyclohexane.
Finally the dispersion was centrifuged at 1000 g for 2 min to remove
larger nanoparticle clusters and the supernatant (containing the
stable nanoparticles) was recuperated.
Iron and cobalt contents in nanoparticles were checked by
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inductively coupled plasma optical emission spectrometer (ICP-AES).
Characterization
SAXS spectra of nanoparticles (corrected for the solvent, cyclohexane)
and the best fitting curve are reported in figure 3.11. The scattering
intensity due to the CoFe2O4 nanoparticles was modeled according to
the formalism introduced by Bartlett and Ottewill for polydisperse
spherical particles5. In this approach, the particles are described as
spherical  core-shell objects with a Schulz distribution of the core
radius and constant thickness of the shell6,10. In particular, the
model accounts for a polydisperse population of spheres with uniform
scattering length density. No structure factors have been included in
this model as, due to the low concentration of particles in the
dispersions, the interparticle interference effects can be neglected.
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Figure 3.11. SAXS spectra of oleic acid coated ( ) cobalt ferrite
nanoparticles
The autocorrelation functions obtained by DLS measurements were
well fitted with Cumulant analysis; the size distribution is shown
in figure 3.12. The hydrodynamic radius calculated by DLS
includes also the oleic acid shells and the solvent layers of the
3- Drug carriers
____________________________________________________________________
93
nano-objects in solution.
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Figure 3.12. Size distribution of oleic-coated Cobalt-ferrite nanoparticles
obtained from DLS analysis.
In table 3.4 the main features of oleic Cobalt-ferrite nanoparticles
were reported.
Table 3.4. Structural parameters of oleic acid coated CoFe2O4 nanoparticles
by SAXS and DLS analysis.
SAXS Fitting
<R> [nm] 7.5
Polydispersity 0.28
Shell thickness [nm] 2.4
Cumulant analysis
RH[nm] 22.4
Polydispersity 0.24
CONTIN
<Rh> [nm] 12.4
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3.4 Fluorescent Cobalt Ferrite
nanoparticles (MP@SiO2(RITC))
Materials: Rhodamine B isothiocyanate (RITC) (λex= 546 nm, λem=
572  nm) ,  t e t rae thy l  o r thos i l i ca te  (TEOS) ,  3 -
aminopropyltriethoxysilane (APTES), tetramethylammonium
hydroxide 25% wt solution in water (TMAOH), chloroform (99.9%
HPLC grade), absolute ethanol (≥ 99.5%) were purchased from Sigma-
Aldrich.  Uncoated negative charged Cobalt-ferrite nanoparticles in
water.
The synthesis of fluorescent silica-coated Cobalt-ferrite nanoparticles
includes two important steps: functionalization of APTES with the
fluorescent molecule RITC (APTES-RITC) and polysiloxane coating of
magnetic NPs with TEOS and APTES-RITC.
- APTES-RITC, aminopropyltriethoxysilane covalently coupled to the
fluorescent dye Rhodamine B, was prepared from APTES (0.0238
mmol) and RITC (0.0124 mmol) dissolved in 8 ml of anhydrous
ethanol. The mixure was stirred for 24 hours in the dark and under
nitrogen11.
- MP@SiO2(RITC) were prepared by a sol-gel method, introducing some
modifications to the standard procedure12. RITC coating of Cobalt
ferrite NPs was obtained by adding to 1 ml of 0.15 M Cobalt ferrite
nanoparticles dispersed in TMAOH, diluted in 3 ml of ethanol, 18 µl
of APTES-RITC and 3µl of TEOS. The reaction was allowed to proceed
at room temperature for 2 hours in the dark under continuous
stirring. The growth of APTES-RITC shells on Cobalt ferrite NP
involved the hydrolysis of TEOS and the condensation of silica on
Cobalt ferrite cores. MP@SiO2(RITC) were separated from the reaction
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medium by centrifugation at 4500 rpm for 20 minutes.  The collected
particles were washed several times with ethanol and then dispersed
in water and dialyzed by means of ultrafiltration (Amicon, Millipore
corporation, membrane of regenerated cellulose, 10 kDa NMWL) in
order to remove any excess of unreacted RITC. Cobalt and iron
contents in MP@SiO2(RITC) were checked by inductively coupled
plasma atomic emission spectrometer (ICP-AES) indicating 950
mg/ml and 1920 mg/ml of Co and Fe respectively.
Characterization
MP@SiO2(RITC) size and shape were observed  by an inverted Optical
Microscope (Nikon Diaphot 300) equipped with a DS-L1 charge-
coupled device camera  (oil immersion objective 100/1x25) and Epi-
Fluorescence Attachement (Nikon HB-10104AF, mercury lamp λexc=
510 nm).
Confocal images of MP@SiO2(RITC) were also acquired by a DMIRE2
Confocal Laser Scanning Microscope (CLSM, Leica TCS SP2) with
argon ion lasers and a water immersion objective 63x/1.2W (Zeiss),
exciting at  λ= 514 nm and acquiring between 560 and 650 nm.
In Figure 3.13 (a,b) microscopy images of the particles are reported,
evidencing fluorescent structures and the presence of some
aggregates of MP@SiO2(RITC) which have tendency to form chains
aligned in a particular  direction because of their magnetic
anisotropy.
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Figure 3.13. (a) CLSM (argon ion laser at λ= 514 nm) images, (b) optical
microscopy images in phase contrast modality of MP@SiO2(RITC).
MP@SiO2(RITC) have the tendency to align in a particular direction because
of the magnetic anisotropy.
The autocorrelation functions, obtained by DLS measurements
performed on MP@SiO2(RITC) solution diluted 100 times with water,
were well fitted with Cumulant analysis. The size distributions of
nanoparticles have been extracted from CONTIN analysis, indicating
the presence of three different populations (see Figure 3.14). In
particular, a CONTIN analysis calculated in function of the number of
nanoparticles has indicated a representative population of
nanoparticles around 50 nm of diameter and the presence of some
larger aggregates of about 180 nm and 350 nm of diameter.
7.34 µm
a) b)
25 µm
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Figure 3.14. Size distribution of MP@SiO2(RITC) nanoparticles obtained
from DLS analysis in function of the number of nanoparticles.
The fluorescence emission spectra of MP@SiO2(RITC) and APTES-
RITC aqueous solutions were acquired exciting at λ= 546 nm
(corresponding to the maximum fluorescence emission) and λ= 514
nm (corresponding to the laser line used for Confocal Microcopy
acquisition). A comparison between MP@SiO2(RITC) and APTES-RITC
fluorescence spectra, reported in Figure 3.15 (a,b), has indicated a
strong red shift effect for MP@SiO2(RITC) due to the interaction of the
dye with Cobalt ferrite NP, confirming  that the APTES-RITC dye is
effectively bounded to magnetic particles.
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Figure 3.15. Fluorescence emission spectra of MP@SiO2(RITC) and free
APTES-RITC in water with excitation set at (a) 546 nm (maximum emission)
and (b) 514 nm (laser line used for CLSM experiments).
a)
b)
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3.5 Liposomes and Magnetoliposomes
Materials: L-α phosphatidylcholine egg yolk Grade 1 (99.9% TLC)
in chloroform (PC) was purchased from Lipid Products. Sodium
hydroxide (98%), sodium chloride (99.5%), 5(6)-carboxyfluorescein
(>>95% HPLC, CF), ethylenediaminetetraacetic acid (EDTA, 99.5%)
were purchased from Sigma-Aldrich. HEPES [4-(2-
hydroxyethyl)piperazine-1-ethane-sulfonic acid] (ultra >>99.5%)
was purchased from Fluka and Sephadex G-25 Superfine from
Pharmacia Fine Chemicals.
Magnetoliposomes were prepared by the extrusion method (see
Methods) where the lipid film hydration is followed by sequential
extrusion13-15.
- Magnetoliposomes with hydrophilic magnetic nanoparticles (uncoated
and citrate-coated Cobalt ferrite NPs) embedded in the aqueous pool
were prepared by evaporation of the solvent from a CHCl3/MeOH
solution of the lipid; the dry lipid film was hydrated with a buffer
solution of Carboxyfluorescein (50 mM CF, 10 mM HEPES, 10 mM
NaCl, 148 mM NaOH, 1 mM EDTA) and magnetic nanoparticles to
give a lipid concentration of 20 mM.
- Magnetoliposomes with hydrophobic magnetic nanoparticles (oleic
acid-coated Cobalt-ferrite NPs) entrapped in the lipid bilayer of the
vesicles were prepared by evaporation of the solvent from a
CHCl3/MeOH solution of the lipid (PC) mixed to an aliquot of Cobalt
ferrite Nps in cyclohexane and then the dry film was hydrated with
the buffer solution of Carboxyfluorescein.
- Control liposomes without Cobalt-ferrite NPs were prepared by
adding only the Carboxyfluorescein solution to the dry lipid film.
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The suspensions were vortexed until complete dispersion of the film
and then frozen-thawed six times. Multilamellar polydisperse vesicles
were then sized down by repeated extrusion at room temperature
through polycarbonate membrane (Whatman). Three steps of twenty-
one extrusions through filters of 0.8 µm, 0.4 µm and 0.2 µm pore
sizes allowed the preparation of a narrow sized distribution of
unilamellar vesicles. The nanoparticles and the molecules of CF that
were not entrapped inside the liposome pool were removed by gel
exclusion chromatography (GEC) with Sephadex G-25 microcolumn
(1 ml-syringe) saturated with lipids so that liposomes were recovered
without dilution.
Under these conditions, 300 µl of liposome dispersions were eluted
and centrifuged at 2000g for two minutes without loss or dilution
of material.
Characterization
Magnetoliposomes with different concentrations of Cobalt ferrite
nanoparticles were prepared and characterized.
The fractions of purified magnetoliposomes were collected and
investigated by DLS in order to have their size distributions. The
autocorrelation functions were well fitted with Cumulant analysis
and the obtained hydrodynamic radii, RH, are ranging between 70-
85 nm and 95-115 nm for liposomes and magnetoliposomes,
respectively, with polydispersity ranging from 0.10 to 0.20. The size
distributions extracted from CONTIN analysis show that
magnetoliposomes are constituted by a single population
(monomodal distribution) centred at the RH value obtained by
Cumulant analysis (see the size distribution of magnetoliposomes
and liposomes in Figure 3.16). No contribution to the overall
scattering intensity arising from the Brownian motion of
nanoparticles could be detected. However, if we externally add to a
liposome solution the same concentration of nanoparticles
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determined in our magnetoliposome samples, the scattering
contribution of the nanoparticles is detectable and the
correspondent autocorrelation function could not be fitted with
Cumulant analysis.
Cobalt-ferrite nanoparticle concentrations were measured by
Inductively Coupled Plasma–Atomic Emission Spectrometry (ICP-
AES), while lipid concentrations after purification by the Steward-
Marshall method16. Steward-Marshall is a colorimetric method
based on the formation of a complex between phospholipid and
ammonium ferrothiocyanate in chloroform; the lipid concentration
is determined from the absorbance read at 485 nm.
The main features of the magnetoliposome dispersions investigated in
this work are reported below and their encapsulation efficiency was
estimated as the ratio of CoFe2O4 concentration before and after GEC
purification.
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Figure 3.16. Representative size distributions of liposomes (grey bars) and
magnetoliposomes (black bars) obtained by CONTIN analysis of the
autocorrelation functions.
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A detailed characterization of magnetoliposomes with hydrophilic and
hydrophobic NPs has been reported in the following paragraphs.
3.5.1 Magnetoliposomes with hydrophilic
nanoparticles
The main features of magnetic nanoparticles embedded in liposome
aqueous pool are reported in table 3.5 (uncoated nanoparticles) and
in table 3.6 (citrate-coated nanoparticles). An estimate of the mean
number of magnetic nanoparticles per liposome, <N>, was calculated
as the ratio of the number of nanoparticles (NNPs) and lipid vescicles
(Nves), <N> = NNPs/Nves, where NNPs and Nves were obtained from their
corresponding size and concentration through the following
equations:
€ 
NNP =
MNP
dNP ⋅ VNP                                                       (3.3)
€ 
Nves =
Vbilayer
Vphospholipid ⋅ Nphospholipid                                       (3.4)
where MNP is the total mass of CoFe2O4 as obtained from ICP-AES, dNP
is the density of CoFe2O4 nanoparticles, VNP is the volume of a single
nanoparticle according to SAXS results, Nves is the total number of
vesicles, Vbilayer is the total volume occupied by the bilayer,
Vphospholipid is the volume occupied by a single lipid molecule and
Nphospholipid is the total number of lipid molecules.
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Table 3.5. Uncoated Cobalt-ferrite nanoparticle loading in the liposomes
MLs Chargea [NPs]
(mg/L)b
<R> (nm)c <RH> (nm)d Encapsulation
Percentagee
<N>f
A (-) 9±0.1 5.7±0.2 84.2±0.7 9.5 0.4
B (-) 37±0.4 5.7±0.2 84.5±0.9 7.4 1.5
C (-) 60±0.6 5.7±0.2 86.7±1.0 6.3 2.5
D (-) 194±2.0 5.7±0.2 90.2±1.2 6.2 8.6
E (-) 162±1.6 23.4±1.0 92.0±1.0 16.2 0.2
F (+) 58±0.6 5.9±0.2 87.9±1.0 6.8 2.6
Table 3.6. Citrate Cobalt-ferrite nanoparticle loading in the liposomes
MLs [NPs] (mg/L)b <R> (nm)c <RH> (nm)d Encapsulation
Percentagee
<N>f
A 216±3 4.9±0.1 95.5±1.1 53.7 2.2
B 449±4 4.9±0.1 96.5±1.2 43.7 4.6
C 2027±20 4.9±0.1 115.5±1.5 39.4 29.8
a Nanoparticle charge
b CoFe2O4 concentration by ICP-AES after GEC purification
c Average radius of nanoparticles by SAXS analysis
d Average hydrodynamic radius of MLs from DLS by CONTIN analysis
e {[CoFe2O4]after GEC/[CoFe2O4]before GEC}×100
f  Mean number of nanoparticles per liposome
From the results reported in tables 3.5 and 3.6, we can see that
the loading of citrate-coated ferrite NPs embedded in liposomes is
more effective compared to the loading obtained for uncoated
nanoparticles. The higher loading of citrate-coated NPs is
reasonably due to their higher stability in buffer medium at pH 7.4
with respect to uncoated NPs.
Magnetoliposomes embedded with citrate-coated nanoparticles
(sample A in Table 3.6) were also characterized by Cryo-TEM
acquisition. Cryo-TEM images (Figure 3.17) show that only some of
the vesicles contain magnetic nanoparticles in their aqueous pool,
while others are completely empty. Moreover the entrapped
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nanoparticles present aggregation, while no specific interaction with
the lipid bilayer can be seen.
   
         
Figure 3.17. Cryo-TEM images of magnetoliposomes embedded with citrate-coated
Cobalt-ferrite nanoparticles (sample A in table 3.6)
3.5.2 Magnetoliposomes with hydrophobic
nanoparticles
The main features of the investigated samples of magnetoliposomes
with oleic acid-coated nanoparticles entrapped in lipid bilayers of
vesicles are reported in Table 3.7.
In order to understand how magnetic nanoparticles interact with the
lipid bilayer of magnetoliposomes, SAXS experiments were carried out
on both liposome (control sample) and magnetoliposome samples.
200 nm 200 nm
200 nm 200 nm
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Table 3.7. Oleic acid-coated cobalt-ferrite nanoparticle loading in the
liposomes
MLs [Nps]
(mg/L)a
<R>b
(nm)
<RH>c
(nm)
PC/CoFe2O4
[w/w]d
Encapsulation
Percentage e
A 26.0±0.3 7.44±0.1 83.5±1.0 550:1 41.7
B 94.0±1.0 7.44±0.1 85.5±1.5 150:1 57.4
C 192.0±2.0 7.44±0.1 86.0±1.5 75:1 60.2
D 205.0±2.0 7.44±0.1 81.5±1.0 110:1 64.1
a CoFe2O4 concentration by ICP-OES after GEC purification
b Average radius of nanoparticles by SAXS analysis
c Average hydrodynamic radius of MLs from DLS by CONTIN analysis
d Weight ratios between phospholipids and nanoparticles
e {[CoFe2O4]after GEC/[CoFe2O4]before GEC}×100
SAXS spectra (reported in Figure 3.18) have been fitted according to a
model proposed by Nallet et al17 for lamellar phases of amphiphilic
bilayer, through the following equation:
€ 
I(Q) = 2πP(Q)2(δH + δT )q2
(3.5)
where the form factor is given by:
€ 
P(Q) = 4q2 ΔρH sin q(δH + δT )[ ] − sin(qδT )[ ] + ΔρT sin(qδT ){ }
2
                         (3.6)
and δH is the head group thickness, δT is the tail length, ΔρH (ρH - ρsolv)
and ΔρT (ρT - ρH) are the scattering length density contrast, where ρH ,
ρT and ρsolv are the scattering length density of head group, tail and
solvent, respectively. In this model no inter-lamellar structure factor
S(Q) is included.
SAXS spectrum of magnetoliposomes has been modelled according to
the following equation:
  
€ 
I (Q) = Iliposomes + I MagNPs + Ibkg             (3.7)
where   
€ 
Iliposomes is the scattering intensity from the liposomes, while
  
€ 
I MagNPs is the scattering intensity arising from magnetic nanoparticles
arranged in fractal clusters and modelled according to the pearl
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necklace model18. We previously used this model to describe
polydisperse spherical nanoparticles with a core-shell structure,
arranged into fractal clusters19. The spherical particles have a
constant shell thickness and a core with a Schulz distribution of
radii19,20. The contribution to the total scattering intensity arising
from these objects was calculated according to:
  
€ 
I MagNPs = φP(Q)S(Q)            (3.8)
where φ is the particle volume fraction, P(Q) is the form factor and
S(Q) is the interparticle structure factor accounting for the
interparticle correlations. The form factor was modelled as:
  
€ 
P(Q) = (1 Vp ) G(rc )F
2(Qrc )drc0
∞
∫ (3.9)
  
€ 
F(Qrc ) = (4π / Q
3 )(ρshell − ρcore ){ρscaled j[Qrc + (t / rc )Qrc] − j(Qrc )} (3.10)
  
€ 
ρscaled = (ρsolv − ρshell )(ρcore − ρshell ) (3.11)
  
€ 
j(Qrc ) = sin(Qrc ) − (Qrc )cos(Qrc ) (3.12)
where rc is the core radius, t is the shell thickness, Vp is the particle
volume, and ρcore, ρshell and ρsolv are the scattering length densities
(SLDs) of the core, shell and solvent, respectively. The function G(rc)
is the normalized probability of finding a particle with a core radius
between rc and rc + drc, and it accounts for the polydispersity of the
cores according to a Schultz distribution10,21.
  
€ 
G(rc) =
rc
Z
Γ(Z +1)
Z +1
rc
 
 
  
 
 
  
Z +1
exp −
rc
ravg
(Z +1)
 
 
 
 
 
                   (3.13)
where Γ(Z + 1) is the gamma function and the parameter Z is related
to the polydispersity σc of the core radius by the expression:
  
€ 
σ c =
( rc
2 − rc
2
)1/ 2
rc
=
1
(Z +1)1/ 2
         (3.14)
The interparticle structure factor S(Q) describes how the scattering
intensity is modulated by interference effects between radiation
scattered by different scattering objects. In our case, it should
account for the aggregation of the magnetic nanoparticles, in analogy
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with the distribution of micelles along the polypeptide backbone.
Therefore, we used the same expression derived by Chen and
Teixeira18:
  
€ 
S(Q) =1+
DΓ(D −1)
(Qr )D
sin[(D −1) tan−1(Qξ] 1+
1
Q2ξ2
 
 
 
 
 
 
(1−D ) / 2
(3.15)
where r is the mean radius of the particles as resulting from the sum
of the core radius rc and the shell thickness t, Γ is the gamma
function and "ξ is the correlation length, i.e. a cut-off factor related to
the dimensions of the aggregates that are eventually formed by the
particles. D is the fractal dimension that describes the spatial
distribution of the individual scatterers and it is related to their
number N(R) within a sphere of radius R through the equation:
  
€ 
N ( R) = ( R / r )D (3.16)
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Figure 3.18. SAXS spectra of liposome (PC 15 mg/ml) and magnetoliposome
(sample C in Table 2) solutions. The best fittings are reported as solid lines.
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Fitting results (reported in Table 3.8) show that the presence of the
magnetic nanoparticles does not affect the structure of the bilayer, as
the experimental SAXS curve is well fitted by the sum of nanoparticle
and bilayer contributions. This schematically corresponds to the
physisorption of aggregates (average dimension around 25 nm) of
magnetically nanoparticles onto the lipid bilayer.
Table 3.8. Structural parameters of liposomes and magnetolipomes by
SAXS analysis
Liposomes Magnetoliposomes
Lipid head group thickness,
δH [Å]
4.5 4.5
Lipid tail length, δT [Å] 17.8 17.8
CoFe2O4 mean core radius,
<R> [Å]
_____ 51.5
CoFe2O4 shell thickness, t
[Å]
_____ 38.1
CoFe2O4 core polidispersity,
σe
_____ 0.29
CoFe2O4 fractal dimension,
D
_____ 2.6
CoFe2O4 correlation length,
ξ [Å]
_____ 255.0
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3.6 Giant Unilamellar Vesicles (GUVs)
Materials: L-α phosphatidylcholine egg yolk Grade 1 (99.9% TLC) in
chloroform (PC) was purchased from Lipid Products. Alexa Fluor 488-
C5 male imide  and Di IC18 (1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate) were purchased from
Invitrogen Molecular Probes. D(+)-Sucrose (≥ 99.5% HPLC) and D-(+)-
Glucose (≥ 99.5% HPLC, sum of enantiomers)  anhydrous were
purchased from Fluka.
GUVs were prepared using the electroformation method, originally
developed by Angelova and Dimitrov by using a homemade chamber
prepared by assembling two Indium Tin Oxide (ITO)-coated
microscope slides separated by an O-ring spacer (see Methods).
The lipid was dissolved in chloroform (PC, 5 mg/ml) with 0.1% mol of
the fluorescent probe DiIC18 (excitation and emission wavelengths are
549 and 565 nm, respectively). A volume of 15 µl of lipid stock
solution was spread on each conducting face of ITO-coated
microscope slides and then dried under vacuum for at least 2 h in
order to remove solvent. An O-ring was positioned around the film,
and the two slides were sandwiched to form a chamber where GUV
growth took place. The chamber was then filled with a buffer solution
(volume 350 µl) of Alexa 488-C5-maleimide 5 µM in sucrose 0.23 M
and equilibrated at room temperature. Magnetic GUVs were prepared
by adding citrate coated NPs in buffer in order to have nanoparticles
and lipid in molar ratio of 2:1.
An analogue preparation was used by adding magnetic and
fluorescent nanoparticles of MP@SiO2(RITC) in order to detect their
location on GUVs. Finally, the chamber was connected to a function
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generator and a low-frequency AC electric field (sinusoidal wave with
a frequency of 10 Hz and amplitude of 2 V) was applied for 3 h. GUV
growth was monitored by optical microscopy and, when complete, the
solution was gently removed from the electro-formation chamber. To
reduce the fluorescence from Alexa molecules not confined within the
GUV, samples were diluted 15 times with an iso-osmolar solution of
glucose 0.23 M. The density difference between sucrose (inner pool)
and glucose (external medium) lead to GUV deposition, helping in
microscopy observation.
The diameter of the vesicles obtained by electro-formation method
ranged from 5 to 50 µm22. A CLSM image of a fluorescent GUV
labeled with the lipophilic marker DiIC18 (red) and filled with the
water-soluble Alexa dye is reported in Figure 3.19.
Figure 3.19. CLSM image of a GUV labeled with DiIC18 (red) and filled with
Alexa dye (green)
3.6.1 GUVs in the presence of MP@SiO2(RITC)
CLSM images of magnetic and fluorescent GUVs are reported in
Figure 3.20, showing that MP@SiO2(RITC) nanoparticles are adsorbed
on the surface of GUVs’bilayer.
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Figure 3.20. CLSM images of magnetic GUVs prepared by electroformation
in the presence of MP@SiO2(RITC).
Three-dimensional projection obtained assembling with Leica
software confocal slices (thickness 0.366 µm) of magnetic GUVs
indicates that MP@SiO2(RITC) were not homogeneously distributed on
the membrane surface of the vesicles (Figure 3.21).
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Figure 3.21. Three-dimensional projection (max fix treatment) of magnetic
GUVs prepared by electroformation in the presence of MP@SiO2(RITC).
Intensity line profiles of different regions of GUV membrane (Figure
3.22) confirm that the magnetic particles are not uniformly
distributed on the lipid bilayer of vesicles, evidencing larger thickness
(ranging between 1 and 4 µm) and higher fluorescent intensity where
MP@SiO2(RITC) are adsorbed.  Moreover, confocal xyλ-scans of
magnetic GUVs were performed to analyze the different fluorescence
spectra in different regions of the membrane, depending on
MP@SiO2(RITC) adsorption, evidencing higher  fluorescent intensity
(maximum emission around λ= 586 nm) in the presence of larger
amounts of adsorbed nanoparticles. These results were compared
with the ones obtained with GUVs hydrated with a solution of free
APTES-RITC in sucrose 0.23 M. Differently from magnetic GUVs,
RITC-labeled GUVs images show a uniform distribution of the
fluorescent dye on the lipid bilayer of vesicles, evidencing the same
membrane thickness (around 0.5 µm) over the entire surface of GUVs
(Figure 3.23).
Empty and non-fluorescent GUVs, also prepared in sucrose, were
mixed to MP@SiO2(RITC) in a way to have [CoFe2O4]/[PC] = 2 and
analyzed by CLSM in order to detect the effect of an external addition
of magnetic particles to pre-formed GUVs.
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Figure 3.22. (a) Different regions (ROI) of GUV membrane prepared in the
presence of MP@SiO2(RITC) (b) intensity line profile spectra of the three
different regions of magnetic GUV membrane.
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Figure 3.23. (a) Different regions (ROI) of GUV membrane labeled with
APTES-RITC (b) intensity line profile spectra of the three different regions of
RITC-labeled GUV membrane.
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Confocal image reported in Figure 3.24 of pre-formed GUVs in the
presence of MP@SiO2(RITC) shows the formation of large aggregates
of magnetic particles and the appearance of some vesicles after the
addition of fluorescent and magnetic nanoparticles to the empty GUV
solution. A shape deformation of some GUVs is observed in the
regions where MP@SiO2(RITC) were present in larger amounts.
Figure 3.24. CLSM image of pre-formed GUVs to which MP@SiO2(RITC) were
added.
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4 - Drug release
4.1 Magnetoliposomes embedded with
hydrophilic nanoparticles
The release of Carboxyfluorescein (CF) from magnetoliposomes
embedded with hydrophilic magnetic nanoparticles was monitored as
the increase of fluorescence emission of CF (see Methods). The
leakage has been measured as a function of the field frequency (0.2
kHz, 2.84 kHz and 5.82 kHz), the time of exposure (10, 20 and 50
min) to the field and concentration of the loaded magnetic
nanoparticles.
Although the release results obtained from magnetoliposomes
embedded with uncoated magnetic NPs were very promising, their
loading and their encapsulation efficiency were quite low with
respect to the citrate-coated ones (see Drug-carriers, Tables 3.5
and 3.6). Furthermore, the stability of the system was strongly
affected by the presence of uncoated NPs, as shown by the
appearance of a black precipitate after few days. The precipitation
of aggregates induced by uncoated CoFe2O4 NPs is a limit to
biomedical applications: in fact, large particles are easily
sequestered by the spleen and eventually removed by the cells of
the phagocyte system, resulting in decreased circulation time.
For these reasons magnetoliposomes loaded with citrate-coated
CoFe2O4 NPs appear more promising for drug delivery applications,
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so I have mainly reported the release results obtained with these
magnetoliposomes, which have a higher stability during time and
optimized release conditions.
However, both magnetoliposome samples (loaded with uncoated or
citrate-coated NPs) have shown a significant increase in their
permeability upon LF-AMF application with respect to a control
sample without nanoparticles and have shown similar release results.
A comparison between the release from liposomes loaded with citrate-
coated Cobalt-ferrite NPs (sample C in Table 3.6) and liposomes
loaded with the uncoated ones (sample A Table 3.5) prepared at the
same concentration (about 200 mg/l of CoFe2O4) and exposed to the
field (5.8 kHz for 50 minutes) has been reported in Figure 4.1.
Figure 4.1. Release curves of control sample, uncoated and citrate coated
nanoparticles-loaded liposomes after LF-AMF exposure at 5.82 kHz for 50
minutes.
Immediately after the LF-AMF exposure magnetoliposmes loaded with
citrate nanoparticles appear less sensitive to the magnetic field (about
25% of CF release) with respect to uncoated nanoparticles-embedded
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vesicles (over 40% of CF release). However, after 30 hours, both
magnetoliposome solutions reach nearly 60% of CF release. The
different behaviour between equally loaded magnetoliposomes can be
explained by taking into account two factors. First, uncoated
magnetic NPs are expected to have a higher electrostatic interaction
with the bilayer as their surface charge is not screened by the citrate
counterions. This would suggest a preferential location of the
nanoparticles next to the bilayer, resulting in the enhancement of the
hyperthermic effect. Secondly, the uncoated magnetic nanoparticles
form large aggregates in the buffer solution. In presence of an
anisotropic magnetic field, as in the case of our home-made
apparatus (see Methods), magnetic nanoparticles are trailed in
opposite directions during the alternating magnetic field cycles.
Larger particles strongly affect the lipid bilayer permeability causing
the formation of pores when they hit the liposome membrane during
these oscillations at the applied magnetic field frequency, promoting
CF release, without the rupture of the vesicles. This was confirmed by
DLS analysis that shows no significant changes in the total scattered
intensity and in the evaluated size distributions. The results reported
below are referred to magnetolipoosmes loaded with citrate-coated
NPs, but similar release trends were obtained with the uncoated
ones.
Magnetoliposomes have shown higher release at longer exposure
times with respect to the empty liposomes, especially when the LF-
AMF is applied for at least 50 minutes. The results, reported in
Figure 4.2a, show about a 10% increase after 10 and 20 minutes of
treatment, while nearly 30% increase after 50 minutes of treatment
was observed. CF release increases in all the samples during time. In
particular, 30 hours after the LF-AMF application, all samples
reached about 50-60% of release. The comparison between the
control samples (liposomes without magnetic NPs) exposed to LF-AMF
for 50 minutes at the highest frequency of oscillation and those
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containing magnetic NPs show that the release is almost the same for
the control samples and the 10-20 minutes treated samples,
especially during the first hours.
Concerning the effect of field frequency, a higher release at high
frequencies for the longer exposure time (Figure 4.2b) was
observed. However, the initial percentage of CF release in
magnetoliposomes exposed for 50 minutes at 0.2 kHz and 2.84 kHz
of field frequency is below 10% and increases up to 50% after 30
hours, similarly to what observed for the control sample (blank in
figure 4.2). On the other hand, at the frequency of 5.82 kHz the
percentage of release is higher (about 30%) and it reaches nearly
60% after 30 hours.
a)
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Figure 4.2. Release of CF-loaded magnetoliposomes (sample C in Table
3.6) in the presence of LF-AMF as a function of (a) exposure time at 5.82
kHz and (b) of field frequency for 50 minutes of treatment. An
enlargement of the release% at t=t0 is shown in the inset.
The release curves of samples with different loading of citrate-
coated CoFe2O4 nanoparticles are reported in Figure 4.3, which
shows that CF release is independent of magnetic fluid
concentration. The percentage of release is almost the same for all
the samples (Table 3.6) exposed to 5.82 kHz field frequency for 50
minutes. After 30 hours the release in liposomes with the lowest
magnetic loading is even higher.
This behaviour is different from what we have observed for
liposomes loaded with uncoated nanoparticles, which have shown
an increase of the percentage of release at higher NP
concentrations. However, uncoated NP loadings are lower than the
citrate-coated ones.
b)
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Figure 4.3. Release curves of CF-loaded magnetoliposomes at different
CoFe2O4 content. The characteristics of these samples are reported in Table
3.6 where they are labeled as A, B, C, respectively.
Upon exposure to the LF-AMF, both magnetoliposomes and control
liposomes have shown a continuos increase of temperature with
time due both to the heat dissipation from the coil and
hyperthermic effects from the NPs. The temperature increase is
slightly higher at higher magnetic fluid loading, showing that the
hyperthermic heating is significant. To evaluate the effect produced
by the heating of the coil, control experiments on both
magnetoliposomes and control liposomes, incubated at the highest
temperature produced by the oscillating field for the total exposure
time, have been performed to take into account the temperature
contribution. We have observed that magnetoliposomes and control
samples (empty liposomes) have similar release trend as a function
of temperature increase. The overall increase due to the
4– Drug release
_____________________________________________________________
123
temperature is never higher than 30% as shown in Figure 4.4 (a, b)
and it is lower with respect to the release percentage due to the
magnetic field exposure.
Therefore, it is very complicated to distinguish the temperature
contribution from the release enhancement due to the LF-AMF
application, though the latter is slightly dominant. From a
comparison with the results obtained for liposomes loaded with
uncoated nanoparticles, we observe that the temperature increase
is proportional to the nanoparticles’ loading, independently of the
presence of the citrate coating, according to the presence of a
hyperthermic effect.
a)
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Figure 4.4. Release curves of (a) CF-loaded magnetoliposomes (sample C
in Table 3.6) and (b) control liposomes incubated at the temperature
indicated in the figure legend
In order to gain a deeper understanding of the magnetic response
of citrate NPs loaded liposomes, AC susceptibility measurements
on a high loading sample (sample C in Table 3.6) were carried out.
Variable temperature AC measurements on ferrofluids can yield
precious information on the mobility of magnetic cores in solution,
and on the nature of the mechanism, underlying the liposome
membrane disruption process at frequencies close to that of LF-
AMF irradiation.
The AC experiment was carried out by scanning the temperature
from 5 K to 310 K in a frequency range of 0.5-1000 Hz with an
amplitude of the oscillating magnetic field of 3.5 Oe (Figure 4.5).
Above ca. 150 K a frequency dependent signal arises in the in-
phase (χ’) component, indicating a Néel type spin relaxation. As
expected, the signal increases with temperature. This behaviour is
b)
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in good agreement with AC measurements on powder indicating
that a large fraction of particles is still blocked at room
temperature.
For high frequency AC fields (n>10 Hz), χ’ increases steadily with
temperature up to 310 K, while a sharp peak appears in the 270-
290 K area for low frequency AC fields: this has to be ascribed to a
minority of particles that are free to rotate under the action of the
alternating field as the aqueous medium melts. However, at higher
temperature the curves resume the trend observed in the frozen
dispersion, confirming that the majority of particles is not
mechanically affected by the oscillating field for frequencies higher
than about 10 Hz. This is confirmed by the out of phase (χ’’)
component of susceptibility, which features a sharp frequency-
dependent peak in the melting temperature region in a background
that, though more noisy, is compatible in the whole temperature
range with the powder-like behaviour (i.e. mechanically blocked
particles).
Altough this investigation was performed at frequencies lower than
that of the optimal LF-AMF experiment (n=5.82 kHz), some
conclusions can be inferred. Indeed it can be reasonably assumed
that no significant difference in the magnetic behaviour is to be
expected between the highest investigated frequency (1000 Hz) and
5820 Hz; thus it can be concluded that in LF-AMF conditions local
hyperthermal heating effects are operative, which are mainly due to
relaxation (Néel) losses and, for a minor component, to frictional
(Brown) losses.
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Figure 4.5. Temperature dependence of the in-phase (a) and out-phase (b)
components of the magnetic susceptibility of a dispersion of liposomes
loaded with citrate coated NPs (sample C in Table 3.6). Darker grey tones
represent increasing frequencies from 0.5 to 1000 Hz; the solid line
represents T= 273K.
As already introduced, in the case of magnetoliposomes loaded
with uncoated Cobalt-ferrite Nps the effect of the size and charge of
nanoparticles has been evaluated. Magnetoliposomes were
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prepared in presence of both negatively and positively-charged
uncoated nanoparticles to highlight possible interactions with
liposome membrane that could enhance or inhibit the effect to LF-
AMF exposure (samples C and F in Table 3.5). Release curves have
shown that negatively charged nanoparticles are more effective in
the same conditions (Figure 4.6a), consistently with a stronger
interaction between positively charged phosphatidylcholine and
negatively charged NPs, taking to an increased permeability of the
membrane. The release is also enhanced by using larger uncoated
nanoparticles (Figure 4.6b, samples D and E in Table 3.5). This can
be explained by two separate effects. In the framework of the
hypothesis we introduced when discussing the effect of the field
frequency, bigger nanoparticles show a stronger response to the
magnetic field, producing then bigger pores when magnetically
collected next to the bilayer. Bigger NPs are also expected to
generate more defects when exposed to oscillating magnetic fields,
both due to their hindrance and to the heat they can produce.
a)
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Figure 4.6. Release curves of CF-loaded magnetoliposomes after LF-AMF
exposure at 5.82 kHz for 50 minutes as a function of (a) uncoated
nanoparticle surface overall charge (samples C and F in Table 3.5) and (b)
nanoparticle size (samples D and E in Table 3.5).
4.1.1 Drug release kinetics
In order to better understand the mechanism of CF release from
magnetoliposomes loaded with magnetic nanoparticles, CF
fluorescence intensity has been monitored during 1000 minutes.
CF release has been investigated in LF-AMF treated and untreated
magnetoliposomes and, for the sake of comparison, in heated
samples. The fluorescence readings were normalized to the
maximum fluorescence intensity of the solution by disrupting the
liposomes with Triton-X 100. The experimental data were fitted
using the Ritger-Peppas equation1-3 widely used to analyze the
release behaviour of various drug delivery systems4-6.
Ritger-Peppas equation can be written as:
€ 
M t
M∞
= Ktn for Mt/M∞ < 0.6                        (4.1)
b)
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where Mt/M∝ is the drug fraction released at time t, K is the kinetic
constant and n is the diffusion exponent that can be related to the
drug transport mechanism. The power-law equation is the
superposition of Fickian diffusion and the so-called “case-II
transport”1,3: when n is between 0.40 and 0.50 (depending on the
matrix geometry) the release follows Fickian diffusion, while “case-
II transport” occurs for n≥1, leading to a zero-order release. For n
values between 0.5 and 1, a so-called “anomalous transport” is
observed and the two processes are coupled.
Occasionally, values of n>>1 has been observed and considered as
kinetics dominated by erosion processes of the matrix (“supercase
II transport”). This equation is generally used to analyze the release
behaviour during the first 60% of the total release. However,
equation 4.1 is based on the assumption that one of the above
mentioned kinetic mechanism of release occurs as soon as the CF
fluorescence intensity is measured. Ford and co-workers7,8
introduced a correction to Ritger and Peppas equation for lag
periods (l):
€ 
Mt
M∞
= k(t − l)m                                                                        (4.2)
The lag period is the time required for the matrix to reach a sort of
equilibrium before a new kinetic mechanism of release occurs,
usually erosion or matrix disruption. Generally, lag periods in
diffusion or dissolution cannot be ignored, despite they are
relatively constant and small, when release mechanisms are
described using exponential functions.
The experimental kinetic curves and the correspondent fittings
obtained with magnetoliposomes loaded with citrate-coated (sample
C of Table 3.6) and uncoated negative (sample C Table 3.5) Cobalt-
ferrite NPs are reported in Figure 4.7a and 4.7b respectively.
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Figure 4.7. (a) Release curves of citrate coated CoFe2O4 NPs-embedded
magnetoliposomes (sample C Table 3.6) in time drive mode and (b) release
curves of uncoated negative CoFe2O4 NPs-embedded magnetoliposomes
(sample C Table 3.5). () Untreated samples, () incubated at 44°C for 50
minutes, () samples subjected to LF-AFM for 50 minutes at a frequency of
5.82 kHz. Solid curves are the best fitting obtained by means of equation
(4.1).
a)
b)
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Kinetics parameters obtained from the analysis of the curves with
equation (4.1) are shown in Table 4.1. For magnetoliposomes
loaded with citrate-coated NPs, untreated samples are well fitted by
equation (4.1) for n equal to 0.57±0.01 indicating that the
dominant drug release mechanism is due to Fickian diffusion. The
fit for magnetoliposomes exposed to LF-AMF and samples
incubated at 44°C gives n=0.80±0.03 and n=0.72±0.01,
respectively, indicating the combination of Fickian diffusion and
initial membrane destabilization. The similar release kinetics
obtained with LF-AMF and heated samples, indicates that both
nanoparticle motions and temperature increase (arising from heat
dissipation from the magnet and from the hyperthermic effect of
NPs) induce an alteration of the lipid bilayer structure that
enhances the CF-release.
For magnetoliposomes loaded with uncoated NPs, the fitting results
give n equal to 0.55±0.01 for untreated samples, indicating Fickian
diffusion, n = 0.76±0.01 for the samples incubated at 38°C,
indicating the presence of anomalous transport, and n = 1.01±0.02
for LF-AMF exposed samples, indicating a zero-order kinetic.
Magnetoliposomes loaded with citrate-coated and uncoated
nanoparticles have shown similar drug-release kinetics, except for
the LF-AMF treated samples. In particular, uncoated magnetic
nanoparticle-embedded liposomes under LF-AMF follow a zero-
order kinetic, confirming that uncoated NPs have a stronger effect
on the lipid bilayer structure with respect to citrate-coated ones.
Generally, K values decrease when passing from Fickian diffusion
to “anomalous transport” and zero-order release. Indeed, the rate
of release is higher at the beginning, when most of the CF is inside
liposomes and diffuses out by concentration gradient. When water
mobility is dominant in penetrating the lipid bilayer as a
consequence of increased porosity due to temperature increase and
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nanoparticle motions under the applied oscillating magnetic field,
the rate of release is slower.
Table 4.1. Kinetic parameters obtained fitting CF release curves of
magnetoliposomes with equation (4.1).
Citrate CoFe2O4 NPs-
loaded
magnetoliposomes
Uncoated CoFe2O4
NPs-loaded
magnetoliposomes
No field
n 0.57±0.01 0.55±0.01
K 3.62⋅10-3±0.13⋅10-3 4.75⋅10-3±0.15⋅10-3
Temperature
n 0.72±0.01 0.76±0.01
K 7.85⋅10-4±0.52⋅10-4 7.02⋅10-4±0.31⋅10-4
LF-AFM
n 0.80±0.03 1.01±0.02
K 3.35⋅10-4±0.68⋅10-4 1.58⋅10-4±0.18⋅10-4
4.1.2 Confocal Laser Scanning microscopy
experiments
To further investigate the leakage behaviour, giant unilamellar
vesicles (GUVs) labeled with DiIC18 and filled with a water soluble
fluorophore (Alexa 488-C5-maleimide) have been prepared (see
Drug carriers) and studied by means of Confocal Laser Scanning
Microscopy (CLSM)9.
The incorporation of a hydrophilic fluorophore in the vesicle pool
allows the direct observation of the variation of fluorescent
intensity during time, which is linked to the probe leakage.
Moreover, the DiIC18 probe was incorporated into GUVs bilayer to
monitor the membrane stability during the experiments. GUVs
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embedded with Cobalt ferrite NPs and control samples (GUVs
without magnetic NPs) have been analyzed by measuring the
change in fluorescence intensity of the Alexa dye inside the GUVs
in a way to check the vesicle permeability changes under LF-AMF.
CLSM experiments with CF-loaded vesicles are not reported
because Carboxyfluorescein undergoes strong photobleaching
when continuously irradiated with the excitation laser source: i.e.,
CF does not allow the distinction between the fluorescence
intensity decrease due to the photobleaching effect or to the field
exposure. Therefore, only Alexa 488-C5-maleimide dye, which has
the same excitation and emission wavelengths of CF, was used to
fill the vesicles, although its molecular weight is higher.
Time-series scans have been performed before, during and after the
application of LF-AMF at the maximum oscillating frequency (5.82
kHz).
Control samples of Alexa-loaded GUVs were scanned under CLSM in
absence and presence of LF-AMF, indicating no change in
fluorescence intensity during time (time-series in Figure 4.8).
Therefore, we can exclude photobleaching of the Alexa fluorescent
probe (green in Figure 4.8) and any significant leakage effect due to
the field exposure of GUVs without magnetic nanoparticles.
Figure 4.8. CLSM images of Alexa-loaded GUV (control sample) in absence
of LF-AMF (a) at time zero and (b) after 30 minutes. Alexa-loaded GUV (c)
exposed for 10 minutes to LF-AMF and (d) 10 minutes after the magnetic
field application.
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On the other hand, some of the Alexa-GUVs loaded with citrate
magnetic nanoparticles have shown a strong effect when exposed
to LF-AMF, as reported in the time-series pictures in Figure 4.9.  In
the absence of the field, magnetic GUVs showed no change in
fluorescent intensity over the investigated period of time (30
minutes), although the initial fluorescent intensity was strongly
lower with respect to the control sample because of the lower
concentration of the embedded Alexa dye when nanoparticles were
loaded inside the vesicles. In the presence of LF-AMF we have
observed a progressive reduction of the fluorescent intensity inside
the vesicles during the exposure time, and this trend proceeds even
after the field removal, as consequence of an increased Alexa
diffusion through the vesicles membrane. The pictures reported in
Figure 4.9 show that the lipid bilayer of GUVs labeled with DiIC18
(red in Figure 4.9) kept unaltered the membrane integrity, even if a
slight reduction of the fluorescent intensity confirms the formation
of pore-like structures at the membrane level that promotes Alexa
leakage.
Figure 4.9. CLSM images of Alexa-loaded GUV with citrate magnetic NPs
(a) in absence of LF-AMF at time zero and (b) after 30 minutes. Magnetic
GUV (c) exposed for 5 minutes and (d) 10 minutes to LF-AMF and (e) 10
minutes after the field application. Magnetic GUV again exposed to LF-
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AMF for (f) 5 minutes and (g) 10 minutes and (h) 10 minutes after the
last field application.
However, other GUVs from the same samples have shown different
behaviour when exposed to the field: some of them strongly
decreased the fluorescent intensity, others did not undergo any
fluorescent changes.  This confirms, as reported in CryoTEM
images (see Drug-carriers), that magnetic nanoparticles are not
present in all GUVs at the same concentration, so that only the
loaded ones have shown Alexa leakage upon LF-AMF exposure.
Moreover, GUVs embedded with uncoated and citrate coated NPs
have shown a similar leakage behaviour, probably because both
nanoparticles (even the uncoated ones) do not form aggregates in
sucrose buffer (in fact no precipitate was observed, even after one
week). In Figures 4.9 and 4.10 we have reported the best Alexa-
release results obtained with GUVs loaded with citrate coated NPs.
 The release rates of Alexa dye from untreated and treated
magnetic GUVs are shown in Figure 4.10, were the relative
fluorescence intensity, calculated as the ratio between the
measured fluorescence intensity at time t and the fluorescence
intensity of the untreated sample at time zero, has been monitored
during time. Magnetic GUVs samples exposed to the field have
shown a strong decrease (20-50%) of the fluorescence intensity
during the experiments.
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Figure 4.10. Alexa release kinetics from magnetic NPs embedded GUVs
before, during and after LF-AMF application.
Therefore, the permeability of GUVs, negligible in absence of LF-AMF,
strongly increased after the field exposure. Finally, those
experimental results support the assumption that LF-AMF changes
GUV permeability in presence of magnetic nanoparticles. However, it
is important to highlight that the release rates obtained by CLSM
experiments are not comparable with the ones obtained by
fluorescence spectroscopy because the systems are different for the
vesicles dimensions, the buffers and the fluorescent probes.
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4.2 Magnetoliposomes embedded with
hydrophobic nanoparticles
The effect of LF-AMF on the stability and release properties of
magnetoliposomes loaded with oleic-acid coated Cobalt-ferrite NPs
was studied by monitoring the increase of fluorescence emission of
CF during time (30 hours). The leakage has been measured as a
function of the field frequency (0.2 kHz, 2.84 kHz and 5.82 kHz), the
time of exposure (10, 20 and 50 min) to the field and concentration of
the magnetic nanoparticles physisorbed on the lipid bilayer of the
vesicles.
Magnetoliposomes (sample B in Table 3.7) show no significant
increase in their permeability upon LF-AMF exposure for the first 5
hours, in fact during this time the release is not much different
with respect to the unexposed sample. However, the CF release
from magnetoliposomes shows a sudden increase after 6 hours and
reaches high percentage (until 90%) after 20 hours (Figure 4.11
a,b). The blank samples (liposomes without nanoparticles) exposed
to LF-AMF at the higher exposure time and field frequency (where
the higher release was observed) have also been investigated and
compared with magnetic liposomes. The treated blank samples,
unlike the treated magnetoliposomes, show no significant release
during all the 30 hours of fluorescence monitoring time.
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Figure 4.11. Release of CF-loaded magnetoliposomes (sample B in Table
3.7) in the presence of LF-AMF as a function of (a) exposure time at 5.2 kHz
and (b) of field frequency for 50 minutes of treatment.
These results indicate that magnetic nanoparticles, entrapped in
the lipid bilayer of magnetoliposomes, effectively affect the bilayer
permeability subsequently to the LF-AMF exposure as a
consequence of their motions due to the applied field frequencies.
a)
b)
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The CF release trend of magnetoliposomes reported in Figure
4.11(a,b) suggests a weak perturbation at the lipid bilayer during
the first 6 hours, followed by a stronger destabilization of the lipid
bilayer, which promotes the sudden CF leakage. The strong
increase of CF leakage, until 90% of the total release, can be due to
the possible rupture of some vesicles. The results obtained for
different exposure time to the LF-AMF are reported in Figure 4.11a
and show that field application of 10 or 20 minutes have similar
behaviour, while longer field exposure time (50 min) lead to higher
release. Figure 4.11b shows the results in function of field
frequency, evidencing higher release for frequencies above 2.5 kHz.
During the exposure to the LF-AMF, magnetoliposomes have shown
an increase of temperature up to 40°C, due to the coils heat
dissipation. Control experiments on magnetoliposomes incubated
at the highest temperature produced by the oscillating field for the
total exposure time have been performed to take into account the
temperature contribution. In Figure 4.12a, CF release experiments
on temperature-treated samples (sample B in Table 3.7) are
reported. Higher temperatures stronger affect the CF release,
however the heating has a lower effect on magnetoliposome
permeability compared to the LF-AMF contribution.
The release experiments with magnetoliposomes at different oleic
acid-coated CoFe2O4 nanoparticles concentrations are reported in
figure 4.12b. Higher loadings are more effective in the CF release
because the presence of high concentrations of magnetic
nanoparticles in the lipid bilayer strongly destabilizes the
liposomes membrane upon LF-AMF exposure. Nanoparticles
oscillations promote the formation of pores at the membrane,
favoring the CF leakage through the lipid bilayer.
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Figure 4.12. (a) Release curves of CF-loaded magnetoliposomes (sample B in
Table 3.7) incubated at the temperature indicated in the figure legend. (b)
Release curves of CF-loaded magnetoliposomes at different oleic-coated
CoFe2O4 NPs content. These are the samples reported in Table 3.7 where
they are labeled as A, B, C, respectively.
CF release results obtained with oleic-coated Cobalt ferrite
a)
b)
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nanoparticles entrapped in the lipid bilayer of liposomes have
shown some differences with respect to the previous results
obtained with naked and citrate-coated cobalt ferrite nanoparticles
embedded in the acqueos pool of magnetoliposomes. In Figure 4.13
release curves of magnetoliposomes loaded with oleic acid-coated,
citrate-coated and uncoated cobalt ferrite nanoparticles (all
prepared at the same concentration of CoFe2O4 ≈ 200 mg/L) and
control liposomes are reported to highlight release differences when
they are exposed for 50 minutes to the oscillating field at 5.2 kHz
of frequency.
As above mentioned, magnetoliposomes with oleic acid-coated
nanoparticles show a very low percentage of CF-release (5%) at the
beginning, pointing out no differences with respect to the control
sample (liposomes without nanoparticles), and they undergo a
sudden increase of leakage only after some hours from LF-AMF
exposure. Otherwise, citrate and naked nanoparticles embedded
liposomes show a higher initial release (25% and 40% respectively),
increasing constantly until 60% of the total leakage after 30 hours.
The different release trend of the investigated magnetoliposomes is
probably due to the different magnetic nanoparticles location: the
lipid bilayer for oleic acid NPs and the aqueous pool of liposomes
for hydrophilic NPs. The greater stability of magnetoliposomes with
oleic acid-coated NPs during the first 6 hours is related to the
presence of hydrophobic NPs within the lipid bilayer, which makes
Carboxyfluorescein diffusion through the lipid bilayer slower and
more difficult. However, the LF-AMF application causes an initial
membrane destabilization, which is followed, about 8 hours later,
by the formation of pores at the membrane that promotes the
sudden CF leakage. The saturation (90% of the total CF leakage) is
quickly reached in less than 30 hours, evidencing the disruption of
liposomes during time. Differently, magnetoliposomes loaded with
hydrophilic NPs show a stronger initial membrane destabilization
4– Drug release
_____________________________________________________________
142
caused by the immediate formation of pores at the lipid bilayer
upon the oscillating field exposure, promoting the instantaneous
release of CF. However, CF leakage during time is slower and more
constant, evidencing no vesicles rupture but only an increased
water mobility through the liposome membrane, which is not
affected by the presence of nanoparticles entrapped in the lipid
bilayer.
Figure 4.13. Release curves of control sample (liposomes without
magnetic nanoparticles) and magnetoliposomes loaded respectively with
naked, citrate-coated and oleic acid-coated nanoparticles after LF-AMF
exposure at 5.2 kHz for 50 minutes.
4.2.1 Magnetoliposome perturbation: DLS and
DSC measurements
Dynamic Light Scattering measurements have been performed on
both oleic acid NP-embedded liposomes exposed and unexposed to
LF-AMF (B 5.2 kHz for 50 min). Moreover, control experiments on
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magnetoliposomes incubated at the highest temperature produced by
the oscillating field for the total exposure time have been performed
to take into account the temperature contribution. The
autocorrelation functions g1(τ) of each sample (untreated, LF-AMF
exposed and 40°C heated magnetoliposomes) have been monitored
every 24 hours during the first three days after the magnetic or
thermal treatments. The results, reported in Figure 4.14 show that
the normalized autocorrelation functions of treated and untreated
solutions coincide, evidencing no perturbation in magnetoliposome
population immediately after the field and the thermal exposure.
Figure 4.14. DLS normalized autocorrelation functions of fresh
magnetoliposome solutions (sample B in Table 3.7): untreated sample at
room temperature, sample exposed at 5.2 kHz for 50 min and sample
incubated at T=40°C for 50 min.
However the autocorrelation functions of the three investigated
samples follow different trends during time: the magnetoliposomes
exposed to LF-AMF significantly changes during time, while the
untreated and temperature incubated samples undergo only slight
changes (Figure 4.15).
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Figure 4.15. DLS normalized autocorrelation functions monitored during
time every 24 hours of (a) the untreated sample without field, (b) the sample
incubated at T=40°C for 50 min and (c) the sample exposed at 5.2 kHz for
50 min.
These results represent a first evidence of the LF-AMF effect on
magnetoliposomes stability, indicating a perturbation of the bilayer
structure due to magnetic nanoparticle oscillations, followed by the
disruption of some vesicles, which occurs many hours after the field
exposure. Moreover, we can state that the temperature weakly affects
magnetoliposome stability, as its behaviour is similar to that of the
untreated sample.
Differential Scanning Calorimetry measurements have been
performed on both liposomes and magnetoliposomes exposed to LF-
AMF. The Figure 4.16 shows the thermograms registered on
liposomes (a) and magnetoliposomes (b) samples every two hours
after the exposure to the magnetic field. The peak, centred around -
22ºC is due to the transition from the lamellar gel (Lβ) phase to the
liquid crystalline (Lα) phase of the PC bilayers. The fact that in the
c)
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liposome sample the peak corresponding to this thermal event is
narrower than in magnetoliposomes suggests that the presence of the
nanoparticles induces a reduction of the cooperativity during the
gel/liquid transition of the lipid bilayers. Moreover the application of
a magnetic field in the presence of the nanoparticles induces the
complete loss of the peak after approximately 8 hours after the
treatment, while the bilayer transition doesn’t change when the
liposome sample is exposed to the field. To highlight this result, the
enthalpies of the gel/liquid transition as a function of time for both
liposome and magnetoliposome samples are reported in figure 4.16c.
DSC experiments support the CF release results, however it’s
important to stress that the disappearance of the gel/liquid transition
peak does not correspond to the rupture of liposomes, as shown by
DLS.
a)
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Figure 4.16. DSC heating curves of (a) liposomes and (b) magnetoliposomes
(sample D in Table 3.7) exposed to LF-AMF (B 5.2 kHz) for 50 min
monitored every two hours during time; (c) enthalpy of gel/liquid transition
(ΔHcal) of liposomes and magnetoliposomes exposed to LF-AMF (B 5.2 kHz)
for 50 min, monitored every two hours after the treatment.
b)
c)
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4.2.2 Drug release kinetics
In order to better understand the mechanism of CF release from
magnetoliposomes with magnetic nanoparticles physisorbed on the
lipid bilayer, CF fluorescence intensity has been monitored during
1200 minutes. CF release has been investigated for LF-AMF treated
and untreated magnetoliposomes and, for the sake of comparison,
in heated samples. The experimental kinetic curves and the
correspondent fittings obtained from Ritger and Peppas equation
are reported in Figure 4.17.
Figure 4.17  Release curves of oleic acid-coated CoFe2O4 NPs embedded-
magnetoliposomes (sample B Table 3.7) in time drive mode. () Untreated
samples, () incubated at 40°C for 50 minutes, () samples exposed to LF-
AFM for 50 minutes at a frequency of 5.2 kHz, where the arrows indicate
the experimental data considered in the curve fitting.  Solid curves are the
best fitting obtained by means of equation (4.1).
Kinetics parameters obtained from the analysis of the curves with
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equation (4.1) are shown in Table 4.2. Untreated samples are well
fitted for n equal to 0.69±0.02 indicating that the dominant drug
release mechanism is the combination of Fickian diffusion and
membrane destabilization due to the presence of hydrophobic NPs
within the lipid bilayer. The fitting curves of magnetoliposomes
incubated at 40°C gives n=1.16±0.03 typical of a zero order kinetic,
indicating membrane erosion or pores formation at the lipid
bilayer, however the rate of release is low. LF-AMF treated samples
show a particular kinetic profile that indicates the presence of two
different release mechanisms: an initial membrane destabilization
during the first 230 minutes (corresponding to the lag time, l)
followed by an exponential burst release with a sigmoid profile. In
this case only the first 230 minutes of CF release data were fitted
by equation (4.1), evidencing a zero order kinetic (n= 1.10±0.07)
characterized by a low rate of release (K=1.20⋅10-4±0.44⋅10-4). The
next burst release, which leads to the complete CF leakage from
LF-AMF treated samples, confirms that nanoparticle motions
induce, after the initial slow membrane erosion, the formation of
large pores at the membrane followed by the vesicles rupture.
K values generally decrease in passing from Fickian diffusion to
“anomalous transport” and zero-order release. This behaviour is
followed also this time by the investigated untreated and treated
samples, indicating a higher rate of release at the beginning, when
most of the CF is inside magnetoliposomes and diffuses out by
concentration gradient.
For LF-AMF exposed samples the presence of a long lag time,
during which the release is very low, before the next burst release
of CF occurred, makes this system a good candidate for controlled
drug delivery. In fact the lag time would allow magnetoliposomes to
reach the target site, avoiding unspecific drug loss during the
transport, and the drug release would occur only at the target site.
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Table 4.2. Kinetic parameters obtained fitting CF release curves of
magnetoliposomes with equation (4.1).
No treatments
n 0.69±0.02
K 1.65⋅10-3±0.21⋅10-3
Temperature
n 1.16±0.03
K 3.02⋅10-5±0.63⋅10-5
LF-AFM From 0 to 230 minutes
n 1.10±0.07
K 1.20⋅10-4±0.44⋅10-4
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4.3 Confocal Laser Scanning Microscopy:
GUVs embedded with MP@SiO2(RITC)
The leakage behaviour from Giant Unilamellar Vesicles was studied
by means of CLSM, loading GUVs with the water-soluble fluorophore
Alexa 488-C5-maleimide. Magnetic GUVs in the presence of
MP@SiO2(RITC) and control samples (GUVs without magnetic
particles) were analyzed by measuring the change in fluorescence
intensity of the Alexa dye inside the GUVs in a way to check the
vesicle permeability changes under LF-AMF. Time-series scans were
carried out before, during (15 min) and after (15 min) the LF-AMF
application at 200 Hz of oscillating field frequency.
Experiments performed on control samples, Alexa-loaded GUVs
(without microparticles) have indicated no changes in the
fluorescence intensity during time. Therefore, we can exclude any
leakage mechanisms due to the LF-AMF exposure of non-magnetic
GUVs and any photobleaching effects of the Alexa dye.
On the other hand, Alexa-loaded GUVs in presence of MP@SiO2(RITC)
have shown a strong release of Alexa due to the LF-AMF exposure, as
reported in the time-series pictures in Figure 4.18. During the LF-
AMF application we observed a progressive reduction of the
fluorescent intensity of Alexa inside the vesicles and this trend
proceeded even after the field removal, as consequence of an
increased Alexa diffusion through the vesicles membrane. It is
interesting to note that, even if the distribution of MP@SiO2(RITC)
onto the membrane is not homogeneous, the Alexa leakage from the
GUVs is uniform, evidencing no preferential paths in the membrane.
However, as shown in Figure 4.19, the rate of release is not constant
during time, but indicates the presence of different processes of
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erosion and pore formation at the membrane during the release
monitoring.
Figure 4.18. CLSM images of Alexa-loaded magnetic GUVs (Alexa in green,
MP@SiO2(RITC) in red). Magnetic GUV (a) in absence of AMF at time zero,
(b) exposed for 8 minutes and (c) 15 minutes to 200 Hz-AMF and (d) 15
minutes after the field application. Magnetic GUV again exposed to 200 Hz-
AMF for (e) 8 minutes and (f) 15 minutes and (g) 15 minutes and 1.5 hour
after the last field application.
Figure 4.19 shown the release kinetics of Alexa dye from magnetic
and non-magnetic GUVs, where the relative fluorescence intensity,
calculated as the ratio between the measured fluorescence intensity
at time t and the fluorescence intensity of the untreated sample at
time zero, were monitored during time. Magnetic GUV samples
exposed to the field have shown a strong decrease (around 50%) of
the fluorescence intensity during the experiments.  Therefore, the
permeability of GUVs, negligible in absence of LF-AMF, strongly
increased after the field exposure. These results, similar to what we
have previously reported for magnetoliposomes loaded with uncoated
4– Drug release
_____________________________________________________________
153
and citrate coated nanoparticles, indicate that the application of LF-
AMF induces an alteration of the lipid bilayer structure (promoting
the formation of pores) that enhances the Alexa-release, without the
rupture of the vesicles.
Figure 4.19. Alexa release kinetics from GUVs in absence  (a) and presence
(b) of MP@SiO2(RITC) during and after LF-AMF applications.
In order to better understand the mechanism involved in the Alexa
leakage, the release kinetic, reported as decrease of the normalized
fluorescence intensity of the dye inside GUVs during time, was
studied by Ritger and Peppas equation written as:
€ 
(I(0) − I(t))
I(∞) = Kt
n                                                                   (4.3)
where [I(0)-I(t)]/I(∞) is the drug fraction release at time t, K is the
kinetic constant and n is the diffusion exponent. The experimental
curve and the corresponding fitting obtained with magnetic GUVs
exposed to the LF-AMF are reported in Figure 4.20.
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The curve is well fitted by equation (4.3) for n equal to 0.67±0.01,
indicating an “anomalous transport” mechanism of release, that is
the combination of Fickian diffusion and membrane perturbation of
GUV. A kinetic constant, K, of 2.3710-3±0.3110-3 indicates a high
rate of release.
Figure 4.20. Alexa release kinetic from GUVs decorated with MP@SiO2(RITC)
exposed to LF-AMF. The solid curve is the fitting obtained by means of
equation (4.3).
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5 - Conclusions
5.1 Final remarks
In this work innovative transport vectors for drug delivery based on
liposomes were employed and their drug release behaviour was
studied.
The ability of liposomes to target a particular tissue or cell, and the
control over the release kinetics was enhanced by introducing
magnetic nanoparticles (Cobalt ferrite, CoFe2O4 NPs) inside lipid
vesicles (in the liposome pool or in the lipid bilayer depending on
nanoparticle properties). The presence of magnetic nanoparticles
allows targeting drugs to a specific location using an external
magnetic force and allows enhancing the drug leakage by applying an
alternating magnetic field (AMF)1,2. In this thesis a low-frequency
alternating magnetic field (LF-AMF), 0.1-6 kHz, was used to study
drug release from magnetoliposomes in order to minimize the
temperature contribution. The enhancement of magnetoliposomes’
permeability was measured as the self-quenching decrease of the
fluorescent hydrophilic molecule (Carboxyfluorescein, CF) entrapped
in the aqueous pool of liposomes.
Hydrophilic and hydrophobic Cobalt ferrite NPs were prepared by co-
precipitation technique and characterized by SAXS (Small Angle X-
Rays Scateering), DLS (Dynamic Light Scattering) and TEM
(Transmission Electron Microscopy) (see Drug-carriers).
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Hydrophilic nanoparticles, uncoated (positively and negatively
charged) and citrate-coated were successfully embedded in the
aqueous pool of liposomes, while the hydrophobic ones, coated with
oleic acid, were entrapped in the lipid bilayer of liposomes.
Magnetoliposomes were prepared by extrusion method and
characterized by DLS, moreover giant unilamellar vesicles (GUVs)
embedded with hydrophilic Cobalt ferrite nanoparticles and
magnetic-fluorescent nanoparticles (MP@SiO2(RITC)) were prepared
by electroformation and analyzed by Confocal Laser Scanning
Microscopy (CLSM) (see Drug-carriers).
All magnetoliposome samples have shown an effective response to LF-
AMF exposure in terms of CF release. The release kinetics were
monitored during time after the magnetic field application and the
drug release kinetics were analyzed by Ritger and Peppas equation in
order to understand the drug transport mechanism. The results have
indicated that, in presence of LF-AMF, both nanoparticles’oscillations
and hyperthermic effect due to the magnetic field anisotropy of the
magnet effectively alter the bilayer structure promoting CF release.
These results were also confirmed by CLSM experiments, which have
shown a progressive leakage of Alexa 488 fluorescent dye, loaded
inside magnetic GUVs, during the application of LF-AMF as
consequence of the formation of pores at the lipid bilayer.
5.1.1 Liposomes loaded with hydrophilic Cobalt
Ferrite nanoparticles
In this work two types of hydrophilic Cobalt ferrite NPs were
prepared: uncoated and citrate-coated NPs. Concerning the uncoated
ones, positively and negatively charged NPs were synthesized, and, in
the case of negatively charged Nps, both small NPs (spheres of about
6 nm of radius) and large NPs (characterized by a representative
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population of spheres of about 23 nm and a minor population of
about 8 nm in radius) were prepared. All these magnetic samples
were successfully embedded in the aqueous pool of liposomes,
however their loading and their encapsulation efficiency were quite
low (see Drug carriers Table 3.5). Furthermore, the stability of
magnetoliposomes was strongly affected by the presence of uncoated
NPs, as shown by the appearance of a black precipitate after few
days. The precipitation, due to the aggregation of nanoparticles is a
limit to biomedical applications. For this reason the nanoparticles
have been stabilized with a citrate coating.
The stability and the loading of citrate-coated Cobalt ferrite NPs
embedded in liposomes were optimized with respect to the uncoated
ones (see Drug carriers Table 3.6).
Both magnetoliposome samples (loaded with uncoated and citrate-
coated NPs) have shown promising release results upon LF-AMF
exposure, indicating higher CF leakage for long field exposure, high
field frequency, high Cobalt ferrite NPs concentration, larger and
negatively charged embedded NPs. A comparison between the release
results obtained with magnetoliposomes embedded with the same
concentration of negative-uncoated and citrate-coated NPs have
shown that the last ones, although the magnetic properties were the
same, have a slower release of CF during time. This different
behaviour can be explained by taking into account a higher
electrostatic interaction of uncoated NPs with the lipid bilayer of
liposomes and their tendency to form larger aggregates; both the
effects lead to the formation of larger pores at the liposome
membrane during the LF-AMF application. Since the citrate coating
of nanoparticles has induced no change in magnetic properties, the
presence of an anisotropic magnetic field, as in the case of our
homemade apparatus, causes the magnetic nanoparticle oscillations
in opposite directions during the alternating magnetic field cycles.
Moreover, AC-susceptibility measurements performed on
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magnetoliposmes (see Release experiments) have indicated that local
hyperthermal effects are operative at the applied field frequencies.
Drug release kinetics of both magnetoliposome samples exposed to
LF-AMF, analyzed by Ritger and Peppas equation, showed a “zero
order kinetic” and an “anomalous transport” mechanism respectively
for uncoated and citrate-coated NPs evidencing in both cases a strong
membrane perturbation. Finally CLSM images acquisition of
magnetic GUVs labeled with DiIC18 and filled with Alexa 488
fluorescent dyes during the magnetic field exposure have confirmed
the results previously discussed: Alexa diffuses out through the
vesicle membrane as consequence of the formation of pore-like
structures at the lipid bilayer without disruption of the lipid
membrane. These results indicate that both the hyperthermic effect
and nanoparticles’ oscillations in the presence of LF-AMF effectively
alter the lipid bilayer structure promoting CF release.
5.1.2 Liposomes loaded with hydrophobic Cobalt
Ferrite nanoparticles
Hydrophobic Cobalt ferrite NPs coated with a shell of oleic acid
(spheres with a core-shell structure of about 10 nm of radius) were
synthesized and successfully entrapped on the lipid bilayer of
liposomes.
SAXS characterization of magnetoliposomes has indicated a
physisorption of aggregates of magnetic NPs onto the lipid bilayer of
liposomes. Magnetoliposome perturbation due to the presence of
Cobalt ferrite NPs upon LF-AMF exposure has been investigated by
DLS and DSC measurements. DLS, DSC and CF release kinetics of
magnetic field treated samples suggest that nanoparticles’
oscillations in the presence of LF-AMF effectively alter the bilayer
structure promoting a initial weak release of CF during the first
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hours, followed by a stronger destabilization of the lipid membrane
due to the formation of larger pores and to the rupture of some
vesicles approximately 8-10 hours after the LF-AMF application. Also
in this case, magnetoliposome response to the oscillating magnetic
field is effective and CF leakage is higher for long LF-AMF exposure
time, high field frequency and high Cobalt ferrite NP concentration.
Drug release kinetics confirmed the presence of an equilibration time,
called “lag period”, during which the release is very low before the
effective burst leakage occurs. The presence of a long “lag period”
makes this system a good candidate for controlled drug delivery as
the magnetoliposmes could reach the targeting site without
unspecific drug loss during the transport.
5.1.3 Giant unilamellar vesicles with
MP@SiO2(RITC)
Magnetic and fluorescent giant unilamellar vesicles (GUVs) in the
presence of MP@SiO2(RITC) were successfully prepared evidencing a
no homogeneous physisorption of nanoparticles on the membrane of
the vesicles. The preparation of these GUVs open the opportunity for
the real observation of membrane perturbations due to an external
stimulus3,4 and the possibility to gain understanding of drug release
mechanism.
The effect of the LF-AMF on the release properties and GUVs
permeability was investigated by acquisition of CLSM images during
time, evidencing a progressive reduction of the Alexa fluorescent
intensity inside the vesicles. As in the previous cases, the
experimental results have indicated an increase of Alexa leakage
through the vesicles membrane, as a consequence of the formation of
pores induced by the magnetic particles’ oscillations during the LF-
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AMF exposure. Drug release kinetics, analyzed by Ritger and Peppas
equation, have shown an “anomalous transport” mechanism.
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